Patents List
Each link below goes to the full text patent. If you wish to view any of the images, you will need to download a viewer available from the US Patent Office.
| Patent No. | Title | Issued |
|---|---|---|
| 7,615,567 | Compounds and methods for promoting smoking cessation | November 10, 2009 |
| Compounds and methods for promoting smoking cessation. The compounds may be used to treat a variety of other conditions and disease states. | ||
| Abstract | Patent Patent Details (US PTO) | ||
| 7,592,277 | Nanofiber mats and production methods thereof | September 22, 2009 |
| An apparatus and method in which the apparatus includes a first electrospinning device configured to electrospin first fibers of a first substance, a second electrospinning device configured to electrospin second fibers of a second substance such that first and second fibers combine in a mat formation region, and a biasing device configured to bias the first electrospinning device with a first electric polarity and to bias the second electrospinning device with a second electric polarity of opposite polarity to the first electric polarity to promote attraction and coalescence between the first and second fibers. The method electrospins under the first electric polarity first fibers from the first substance, electrospins under the second electric polarity fibers from the second substance, and coalesces the first and second fibers to form the fiber mat. | ||
| Abstract | Patent Patent Details (US PTO) | ||
| 7,544,696 | Spermicidal and/or antifungal composition and methods of using the same | June 9, 2009 |
| Hexahydroindenopyridine compounds are provided which act as spermicides and/or fungicides, spermicidal and/or fungicidal compositions containing the same, and methods for killing motile sperm and/or fungi using the compounds and compositions. | ||
| Abstract | Patent Patent Details (US PTO) | ||
| 7,523,617 | Thin film thermoelectric devices for hot-spot thermal management in microprocessors and other electronics | April 28, 2009 |
| A structure, system and method for controlling a temperature of a heat generating device in a solid medium, wherein heat is extracted from the medium into at least one heat extraction device, the heat extraction device dissipates heat into an environment apart from the medium by a heat sink thermally coupled to the heat extraction device; and heat from the medium is dissipated into the heat sink by a first thermal interface material thermally coupling the heat sink to the medium. | ||
| Abstract | Patent Patent Details (US PTO) | ||
| 7,496,295 | Optical-inclusive dWDM local area network | February 24, 2009 |
| An optical-inclusive, dWDM local area network and the accompanying signaling protocol necessary to facilitate communication between nodes in a network. This network architecture provides for a packet-oriented network, independent of the number of nodes and the number of supported wavelengths, and provides for scheduled access to the medium, which guarantees higher utilization. | ||
| Abstract | Patent Patent Details (US PTO) | ||
| 7,495,638 | Visual display with increased field of view | February 24, 2009 |
| This invention provides a continuous display with non-uniform pixel density, forming a foveated display. A single, continuous display has a higher pixel density at the center of the display than at the periphery of the display. Where two continuous displays are used in accordance with the present invention, the central forward gaze of the viewer's image will be displayed in high resolution while the leftmost portion of the left eye display will be in low resolution and the rightmost portion of the right eye display will be in low resolution. The pixel resolution of the visual display may correspond to the visual acuity of the human eye. A foveated image display system using a continuous display with non-uniform pixel density increases the field of view while reducing the image bandwidth. A foveated image display system may be hardware-based by employing anamorphic lenses or sensors rather than relying upon image interpolation to modify the resolution of the resultant image data communicated to the continuous display with non-uniform pixel density. | ||
| Abstract | Patent Patent Details (US PTO) | ||
| 7,476,679 | Octahydroisoquinoline compounds as opioid receptor modulators | January 13, 2009 |
| Compounds which bind to opioid receptors are provided. In a preferred embodiment of the invention, the compounds are opioid receptor antagonists. The present invention also provides methods of treating conditions which are mediated by an opioid receptor. | ||
| Abstract | Patent Patent Details (US PTO) | ||
| 7,449,821 | Piezoelectric micromachined ultrasonic transducer with air-backed cavities | November 11, 2008 |
| A piezoelectric micromachined ultrasonic transducer comprising a substrate and a first dielectric film formed on the substrate. An opening having a sidewall is formed through the substrate and first dielectric film. A bottom electrode is formed on the first dielectric film spanning the opening. A piezoelectric element is formed on the bottom electrode. A second dielectric film surrounds the piezoelectric element. A conformal insulating film is formed on the sidewall of the opening. A conformal conductive film is formed in contact with the bottom electrode and on the sidewall of the opening, wherein an open cavity is maintained in the opening. A top electrode is formed in contact with the piezoelectric element. | ||
| Abstract | Patent Details (US PTO) | ||
| 7,399,762 | Opioid receptor agonist compounds and their use in treatment of pain | July 15, 2008 |
| Structurally novel opioid receptor agonists are provided, and the use of these agonists in treatment of chronic and/or acute pain. | ||
| Abstract | Patent Details (US PTO) | ||
| 7,350,234 | Intrusion tolerant communication networks and associated methods | March 25, 2008 |
| An intrusion tolerant communication network and related methods is provided that places emphasis on continuity of operation and provides for an attack-survivable communication network whose network devices collectively accomplish the specified networking intent even under attack and despite active intrusions. The present invention defines methods for network intrusion tolerance in terms of the various state transitions that maximize the overall effectiveness of an intrusion tolerant communication network. | ||
| Abstract | Patent Details (US PTO) | ||
| 7,342,169 | Phonon-blocking, electron-transmitting low-dimensional structures | March 11, 2008 |
| A thermoelectric structure and device including at least first and second material systems having different lattice constants and interposed in contact with each other, and a physical interface at which the at least first and second material systems are joined with a lattice mismatch and at which structural integrity of the first and second material systems is substantially maintained. The at least first and second material systems have a charge carrier transport direction normal to the physical interface and preferably periodically arranged in a superlattice structure. | ||
| Abstract | Patent Details (US PTO) | ||
| 7,297,305 | Electrospinning in a controlled gaseous environment | November 20, 2007 |
| Apparatus and method for producing fibrous materials in which the apparatus includes an extrusion element configured to electrospin a substance from which the fibers are to be composed by an electric field extraction of the substance from a tip of the extrusion element, a collector disposed from the extrusion element and configured to collect the fibers, a chamber enclosing the collector and the extrusion element, and a control mechanism configured to control a gaseous environment in which the fibers are to be electrospun. The method includes providing a substance from which the fibers are to be composed to a tip of an extrusion element, applying an electric field to the extrusion element in a direction of the tip, controlling a gaseous environment about where the fibers are to be electrospun, and electrospinning the substance from the tip of the extrusion element by an electric field extraction of the substance from the tip into the controlled gaseous environment. | ||
| Abstract | Patent Details (US PTO) | ||
| 7,291,737 | Cocaine receptor binding ligands | November 6, 2007 |
| A class of binding ligands for cocaine receptors and other receptors in the brain. Specifically, a novel family of compounds shows high binding specificity and activity, and, in a radiolabeled form, can be used to bind to these receptors, for biochemical assays and imaging techniques. Such imaging is useful for determining effective doses of new drug candidates in human populations. In addition, the high specificity, slow onset and long duration of the action of these compounds at the receptors makes them particularly well suited for therapeutic uses, for example as substitute medication for psychostimulant abuse. Some of these compounds may be useful in treating Parkinson's Disease or depression, by virtue of their inhibitory properties at monoamine transporters. | ||
| Abstract | Patent Details (US PTO) | ||
| 7,291,259 | Process for desulfurizing hydrocarbon fuels and fuel components | November 6, 2007 |
| Processes are disclosed for removing sulfur, including cyclic and polycyclic organic sulfur components such as thiophenes and benzothiophenes, from a hydrocarbon feedstock including fuels and fuel components. The feedstock is contacted with a regenerable sorbent material capable of selectively adsorbing the sulfur compounds present in the hydrocarbon feedstock in the absence of a hydrodesulfurization catalyst. In one embodiment, the sorbent can be an active metal oxide sulfur sorbent in combination with a refractory inorganic oxide cracking catalyst support. In another embodiment, the sorbent can be a metal-substituted refractory inorganic oxide cracking catalyst wherein the metal is a metal which is capable in its oxide form, of adsorption of reduced sulfur compounds by conversion of the metal oxide to a metal sulfide. The processes are preferably carried out in a transport bed reactor. | ||
| Abstract | Patent Details (US PTO) | ||
| 7,282,798 | Spontaneous emission enhanced heat transport method and structures for cooling, sensing, and power generation | October 16, 2007 |
| A method and structure for heat transport, cooling, sensing and power generation is described. A photonic bandgap structure (3) is employed to enhance emissive heat transport from heat sources such as integrated circuits (2) to heat spreaders (4). The photonic bandgap structure (3) is also employed to convert heat to electric power by enhanced emission absorption and to cool and sense radiation, such as infra-red radiation. These concepts may be applied to both heat loss and heat absorption, and may be applied to heat transport and absorption enhancement in a single device. | ||
| Abstract | Patent Details (US PTO) | ||
| 7,259,286 | Attrition resistant bulk iron catalysts and processes for preparing and using same | August 21, 2007 |
| An attrition resistant precipitated bulk iron catalyst is prepared from iron oxide precursor and a binder by spray drying. The catalysts are preferably used in carbon monoxide hydrogenation processes such as Fischer-Tropsch synthesis. These catalysts are suitable for use in fluidized-bed reactors, transport reactors and, especially, slurry bubble column reactors. | ||
| Abstract | Patent Details (US PTO) | ||
| 7,189,737 | Cocaine receptor binding ligands | March 13, 2007 |
| A class of binding ligands for cocaine receptors and other receptors in the brain. Specifically, a novel family of compounds shows high binding specificity and activity, and, in a radiolabeled form, can be used to bind to these receptors, for biochemical assays and imaging techniques. Such imaging is useful for determining effective doses of new drug candidates in human populations. In addition, the high specificity, slow onset and long duration of the action of these compounds at the receptors makes them particularly well suited for therapeutic uses, for example as substitute medication for psychostimulant abuse. Some of these compounds may be useful in treating Parkinson's Disease or depression, by virtue of their inhibitory properties at monoamine transporters. | ||
| Abstract | Patent Details (US PTO) | ||
| 7,164,077 | Thin-film thermoelectric cooling and heating devices for DNA genomic and proteomic chips, thermo-optical switching circuits, and IR tags | January 16, 2007 |
| A thermoelectric cooling and heating device including a substrate, a plurality of thermoelectric elements arranged on one side of the substrate and configured to perform at least one of selective heating and cooling such that each thermoelectric element includes a thermoelectric material, a Peltier contact contacting the thermoelectric material and forming under electrical current flow at least one of a heated junction and a cooled junction, and electrodes configured to provide current through the thermoelectric material and the Peltier contact. As such, the thermoelectric cooling and heating device selectively biases the thermoelectric elements to provide on one side of the thermolectric device a grid of localized heated or cooled junctions. | ||
| Abstract | Patent Details (US PTO) | ||
| 7,134,857 | Electrospinning of fibers using a rotatable spray head | November 14, 2006 |
| Apparatus and method for electrospinning fibers in which the apparatus includes a spray head having a longitudinal axis and including at least one electrospinning element disposed in a peripheral wall of the spray head surrounding the longitudinal axis. The electrospinning element includes a passage by which a substance from which the fibers are to be electrospun is provided to a tip of the extrusion electrospinning element. The electrospinning element extends from the peripheral wall in a direction from the longitudinal axis and is configured to electrospin the fibers by electric field extraction of the substance from the tip of the extrusion electrospinning element. Accordingly, the method includes providing a substance from which the fibers are to be composed to a tip of an electrospinning element in a peripheral wall of a spray head having a longitudinal axis, rotating the spray head or a collector configured to receive the fibers around the longitudinal axis, applying in a direction from the longitudinal axis of the spray head an electric field to the tip of the electrospinning element to electrospin by electric field extraction the substance from the tip of the electrospinning element to form the fibers, and collecting the fibers on the collector. | ||
| Abstract | Patent Details (US PTO) | ||
| 7,112,536 | Plasma processing system and method | September 26, 2006 |
| A plasma processing system and method wherein a power source produces a magnetic field and an electric field, and a window disposed between the power source and an interior of a plasma chamber couples the magnetic field into the plasma chamber thereby to couple power inductively into the chamber and based thereon produce a plasma in the plasma chamber. The window can be shaped and dimensioned to control an amount of power capacitively coupled to the plasma chamber by means of the electric field so that the amount of capacitively coupled power is selected in a range from zero to a predetermined amount. Also, a tuned antenna strap having r.f. power applied thereto to produce a standing wave therein can be arranged adjacent the window to couple magnetic field from a current maximum formed in the strap to the interior of the chamber. A desired amount of magnetic field and/or electric field coupling can be produced by arrangement of the chamber window adjacent that portion of the antenna strap exhibiting the desired current/voltage relationship. The system may be formed in a line source configuration, or in a cylindrical source configuration. The window may have slots and/or apertures, the size and shape of which may be variable. | ||
| Abstract | Patent Details (US PTO) | ||
| 7,076,801 | Intrusion tolerant server system | July 11, 2006 |
| The invention relates to a reconfigurable scalable intrusion-tolerant network that is interposed between a service requesting client and a protected server to minimize the impact of intrusive events. The apparatus may include a proxy server for receiving the requests from a client and forwarding them to a protected server. Acceptance monitors receive the response from a protected server and apply one or more acceptance tests. A ballot monitor receives the result of the acceptance tests and determines a response to the client. The network may also include an intrusion sensor to detect threats to the network and a reconfigurer to alter the network forwarding scheme. Reconfiguration may include isolating network elements, creating parallel paths, implementing redundant operations, or assessing the validity of responses. | ||
| Abstract | Patent Details (US PTO) | ||
| 7,071,204 | Camptothecin analogs having an E-ring ketone | July 4, 2006 |
| Camptothecin analogs having an E-ring ketone are effective anti tumor compounds. These compounds inhibit the enzyme topoisomerase I and may alkylate DNA of the associated topoisomerase I DNA cleavable complex. | ||
| Abstract | Patent Details (US PTO) | ||
| 7,067,666 | 7-substituted camptothecin and camptothecin analogs and methods for producing the same | June 27, 2006 |
| Methods of forming camptothecin compounds which are effective anti-tumor compounds are disclosed. These compounds inhibit the enzyme topoisomerase I and may alkylate DNA of the associated topoisomerase I-DNA cleavable complex. | ||
| Abstract | Patent Details (US PTO) | ||
| 7,067,093 | Attrition resistant, zinc titanate-containing, reduced sulfur sorbents and methods of use thereof | June 27, 2006 |
| Reduced sulfur gas species (e.g., H.sub.2S, COS and CS.sub.2) are removed from a gas stream by compositions wherein a zinc titanate ingredient is associated with a metal oxide-aluminate phase material in the same particle species. Nonlimiting examples of metal oxides comprising the compositions include magnesium oxide, zinc oxide, calcium oxide, nickel oxide, etc. | ||
| Abstract | Patent Details (US PTO) | ||
| 7,058,638 | Method for statistical disclosure limitation | June 6, 2006 |
| A method and system for ensuring statistical disclosure limitation (SDL) of categorical or continuous micro data, while maintaining the analytical quality of the micro data. The new SDL methodology exploits the analogy between (1) taking a sample (instead of a census,) along with some adjustments, including imputation, for missing information, and (2) releasing a subset, instead of the original data set, along with some adjustments for records still at disclosure risk. Survey sampling reduces monetary cost in comparison to a census, but entails some loss of information. Similarly, releasing a subset reduces disclosure cost in comparison to the full database, but entails some loss of information. Thus, optimal survey sampling methods can be used for statistical disclosure limitation. The method includes partitioning the database into risk strata, optimal probabilistic substitution, optimal probabilistic subsampling, and optimal sampling weight calibration. | ||
| Abstract | Patent Details (US PTO) | ||
| 7,042,306 | Three dimensional multimode and optical coupling devices | May 9, 2006 |
| Three dimensional electronic and optical coupling devices that are capable of providing high speed coupling over a large frequency range while limiting the amount of space consumption in the communications network. An optical or electrical coupling device comprises a first substrate and a second substrate adjacent to the first substrate having one or more optical waveguides or microstrips formed thereon. The substrates will have disposed thereon conductive microstrips and/or dielectric elements. The one or more optical waveguides or microstrips formed on the first substrate correspond to at least one optical waveguides or microstrips formed on the second substrate so as to facilitate optical coupling between the corresponding waveguides. Precise spacing between the substrates and precise spacing between the optical waveguides or microstrips facilitate the requisite optical/RF coupling. | ||
| Abstract | Patent Details (US PTO) | ||
| 7,026,602 | Electromagnetic radiation detectors having a microelectromechanical shutter device | April 11, 2006 |
| The present invention provides for an improved electromagnetic radiation detector having a micromachined electrostatic chopper/shutter device. The MEMS flexible film chopper/shutter device provides reliability, efficiency, noise reduction and temperature fluctuation compensation capabilities to the associated electromagnetic radiation detector. An electromagnetic radiation detector having an electrostatic chopper/shutter device includes a detector material element and flexible film actuator overlying the detector material layer and moveable relative thereto. The flexible film actuator will typically include an electrode element and a biasing element such that the actuator remains in a fully curled, open state absent electrostatic voltage and moves to a fully uncurled, closed state upon the application of electrostatic voltage. Arrays that incorporate a plurality of electromagnetic radiation detectors and/or electrostatic shuttering devices are additionally provided for. | ||
| Abstract | Patent Details (US PTO) | ||
| 7,018,991 | 17.beta.-amino and hydroxylamino-11 .beta.-arylsteroids and their derivatives having agonist or antagonist hormonal properties | March 28, 2006 |
| The invention is directed to a novel class of steroids which exhibit potent antiprogestational activity. | ||
| Abstract | Patent Details (US PTO) | ||
| 7,011,813 | Cocaine receptor binding ligands | March 14, 2006 |
| Tropane derivatives having a high binding affinity and selectivity for dopamine transporters bear, on the tropane backbone either a carboxylic ester or isoxazole moiety, as well as a substituted phenyl moiety. The compounds have utility both as pharmaceutical and as imaging agents, when one or more atoms are radioactive. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,974,824 | Kappa opioid receptor ligands | December 13, 2005 |
| Kappa opioid receptor antagonists are provided that yield significant improvements in functional binding assays to kappa opioid receptors relative to nor-BNI, and the use of these antagonists in treatment of disease states that are ameliorated by binding of the kappa opioid receptor such as heroin or cocaine addictions. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,972,889 | Mems electrostatically actuated optical display device and associated arrays | December 6, 2005 |
| A simplified MEMS optical display device driven by electrostatic forces and associated arrays are provided for. The optical display device includes an optically transparent substrate, an optically transparent fixed electrode disposed on the substrate and a pigmented translucent film disposed on the substrate. A moveable optical shutter is affixed to the substrate and is generally aligned with the fixed electrode and the pigmented translucent film. The moveable optical shutter comprises an electrode element and a biasing element. In addition, a fixed portion attached to the substrate and a distal portion adjacent to the fixed portion defines the optical shutter. When an electrostatic voltage differential is established between the fixed electrode and the optical shutter electrode element the distal portion of the optical shutter will move to controllably regulate the pigmentation of an optical signal. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,962,683 | Method of removing and recovering elemental sulfur from highly reducing gas streams containing sulfur gases | November 8, 2005 |
| A method is provided for removal of sulfur gases and recovery of elemental sulfur from sulfur gas containing supply streams, such as syngas or coal gas, by contacting the supply stream with a catalyst, that is either an activated carbon or an oxide based catalyst, and an oxidant, such as sulfur dioxide, in a reaction medium such as molten sulfur, to convert the sulfur gases in the supply stream to elemental sulfur, and recovering the elemental sulfur by separation from the reaction medium. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,951,635 | Zinc oxide-based sorbents and processes for preparing and using same | October 4, 2005 |
| Zinc oxide-based sorbents, and processes for preparing and using them are provided, wherein the sorbents are preferably used to remove one or more reduced sulfur species from gas streams. The sorbents contain an active zinc component, optionally in combination with one or more promoter components and/or one or more substantially inert components. The active zinc component is a two phase material, consisting essentially of a zinc oxide (ZnO) phase and a zinc aluminate (ZnAl.sub.2 O.sub.4) phase. Each of the two phases is characterized by a relatively small crystallite size of typically less than about 500 Angstroms. Preferably the sorbents are prepared by converting a precursor mixture, containing a precipitated zinc oxide precursor and a precipitated aluminum oxide precursor, to the two-phase, active zinc oxide containing component. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,924,921 | Layered photonic crystals | August 2, 2005 |
| A three dimensional photonic crystal and layer-by-layer processes of fabricating the photonic crystal. A substrate is exposed to a plurality of first microspheres made of a first material, the first material being of a type that will bond to the templated substrate and form a self-passivated layer of first microspheres to produce a first layer. The first layer is exposed to a plurality of second microspheres made of a second material, the second material being of a type that will bond to the first layer and form a self-passivated layer of second microspheres. This layering of alternating first and second microspheres can be repeated as desired to build a three dimensional photonic crystal of desired geometry. Charged polymers such as polyelectrolyte coatings can be used to create the bonds. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,907,130 | Speech processing system and method using pseudospontaneous stimulation | June 14, 2005 |
| A apparatus and method for inner ear implants is provided that generates signal processing stochastic independence activity across the excited neural population. A high rate pulse train can produce random spike patterns in auditory nerve fibers (hereafter "pseudospontaneous activity") that are statistically similar to those produced by spontaneous activity in the normal auditory nerve. We call this activity "pseudospontaneous". Varying rates of pseudospontaneous activity can be created by varying the intensity of a fixed amplitude, high rate pulse train stimulus, e.g., 5000 pps. The high rate pulse train can desynchronize the nerve fiber population and can be combined with a data signal in an inner ear implant. The pseudospontaneous activity can enhance neural representation of temporal detail and dynamic range with an inner ear implant such as a cochlear implant. The pseudospontaneous activity can further eliminate a major difference between acoustic-and electrical-derived hearing percepts. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,906,598 | Three dimensional multimode and optical coupling devices | June 14, 2005 |
| Three dimensional electronic and optical coupling devices that are capable of providing high speed coupling over a large frequency range while limiting the amount of space consumption in the communications network. An optical or electrical coupling device comprises a first substrate and a second substrate adjacent to the first substrate having one or more optical waveguides or microstrips formed thereon. The substrates will have disposed thereon conductive microstrips and/or dielectric elements. The one or more optical waveguides or microstrips formed on the first substrate correspond to at least one optical waveguides or microstrips formed on the second substrate so as to facilitate optical coupling between the corresponding waveguides. Precise spacing between the substrates and precise spacing between the optical waveguides or microstrips facilitate the requisite optical/RF coupling. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,900,228 | Opiate compounds, methods of making and methods of use | May 31, 2005 |
| The present application relates to novel opioid receptor antagonists and agonists, methods of making these compounds, and methods of use thereof. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,864,248 | Androgenic steroid compounds and a method of making and using the same | March 8, 2005 |
| An androgenic steroid compound of the formula: ##STR1## wherein: X, Y, Z, R.sup.1, R.sup.2, R.sup.3, R.sup.5 and R.sup.6 are as defined herein. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,832,029 | Impedance control devices for use in the transition regions of electromagnetic and optical circuitry and methods for using the same | December 14, 2004 |
| Impedance control elements that are implemented in conjunction with the transition region of an electromagnetic waveguide to diminish the effect of reflective pulses on the signal transmission and to create linear impedance transition in the transition region are provided for. The device of the present invention provides the stated benefits in electromagnetic waveguides that are capable of high bandwidth signal transmission. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,825,206 | Camptothecin compounds with a thioether group | November 30, 2004 |
| Camptothecin compounds which are effective anti-tumor compounds are disclosed. These conjugates inhibit the enzyme topoisomerase I and enhance the stability of the topoisomerase I-DNA cleavable complex. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,825,209 | Compounds having unique CB1 receptor binding selectivity and methods for their production and use | November 30, 2004 |
| Compounds are provided that are amide analogs of SR141716A having unique CB1 receptor selectivity and providing WIN sparing binding characteristics, pharmaceutical compositions containing the compounds and their use in a method of treatment of CB1 receptor related disorders, such as obesity, schizophrenia, memory dysfunction and marijuana abuse. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,812,189 | Attrition resistant, zinc titanate-containing, reduced sulfur sorbents | November 2, 2004 |
| The disclosure is directed to sorbent compositions for removing reduced sulfur species (e.g., H.sub.2 S, COS and CS.sub.2) a feed stream. The sorbent is formed from a multi-phase composition including a zinc titanate phase and a zinc oxide-aluminate phase. The sorbent composition is substantially free of unreacted alumina. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,763,156 | Flexible optoelectronic circuit and associated method | July 13, 2004 |
| A flexible optoelectronic circuit is assembled on and released from a substrate, and therefore independent of a substrate. The substrate includes semiconductor substrates having a release layer. The release layer is etched to release the optoelectronic circuit such that the resulting circuit is flexible. Both optical elements, such as waveguides, and conductive elements are formed in layers, generally between insulating layers. The elements may be formed and patterned using standard semiconductor manufacturing techniques. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,761,929 | Method for preparation of thermally and mechanically stable metal/porous substrate composite membranes | July 13, 2004 |
| A method is provided for the preparation of metal/porous substrate composite membranes by flowing a solution of metal to be plated over a first surface of a porous substrate and concurrently applying a pressure of gas on a second surface of the porous substrate, such that the porous substrate separates the solution of metal from the gas, and the use of the resulting membrane for the production of highly purified hydrogen gas. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,740,645 | 17.beta.-acyl-17.alpha.-propynyl-11.beta.-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties | May 25, 2004 |
| The invention is directed to a novel class of 17.beta.-acyl-17.alpha.-propynyl steroids which exhibit potent antiprogestational activity. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,722,140 | Cascade cryogenic thermoelectric cooler for cryogenic and room temperature applications | April 20, 2004 |
| A cascade thermoelectric cooler designed to cool to cryogenic temperatures of 30 to 120 K integrates high performance.backslash.high-ZT Bi.sub.x Sb.sub.2-x Te.sub.3 and Bi.sub.2 Te.sub.3-x Se.sub.3 -based super-lattice-structure thin-film thermoelectric devices with a bulk-material based thermoelectric cooler including plural cascaded cold stages with each successive cascaded cold stage able to cool to a progressively lower temperature. Each cold stage in the bulk-material thermoelectric cooler includes a heat source plate, a heat sink plate, a p-type thermoelectric, and a n-type thermoelectric. Moreover, the thin-film thermoelectric cooler can have multiple stages in which each stage contains a heat source plate, a heat sink plate, a p-type super-latticed thermoelectric element, and a n type super-latticed thermoelectric element. By bonding an output heat source plate on the thin-film thermoelectric cooler to an input heat sink plate on the bulk-material thermoelectric cooler, the integration of the thin-film thermoelectric with the bulk-material-based thermoelectric yields a cascade thermoelectric cooler wherein the bulk-material-based thermoelectric cooler cools to 160 K and the thin-film thermoelectric device cools to cryogenic temperatures between 70 and 120 K. Another level of thin-film super-lattice integration can achieve temperatures of 30 K. Alternatively, the integration of a high ZT thin-film superlattice thermoelectric cooler on a multi-staged bulk-material-based thermoelectric cooler can produce a higher performance non-cryogenic cooler. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,706,880 | Cocaine receptor binding ligands | March 16, 2004 |
| The invention relates to novel compounds which show high affinity for cocaine receptors in the brain, particularly dopamine and serotonin transporter sites. The compounds may be used as imaging or pharmaceutical agents, in the diagnosis and treatment of drug addiction, depression, anorexia and neurodegenerative diseases or in determining the doses of therapeutic agents that occupy significant numbers of receptors. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,670,352 | Androgenic steroid compounds and a method of making and using the same | December 30, 2003 |
| An androgenic steroid compound of the formula: ##STR1## wherein: X, Y, Z, R.sup.1, R.sup.2, R.sup.3, R.sup.5 and R.sup.6 are as defined herein. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,662,570 | Cascade cryogenic thermoelectric cooler for cryogenic and room temperature applications | December 16, 2003 |
| A cascade thermoelectric cooler designed to cool to cryogenic temperatures of 30 to 120 K integrates high performance.backslash.high-ZT Bi.sub.x Sb.sub.2-x Te.sub.3 and Bi.sub.2 Te.sub.3-x Se.sub.3 -based super-lattice-structure thin-film thermoelectric devices with a bulk-material based thermoelectric cooler including plural cascaded cold stages with each successive cascaded cold stage able to cool to a progressively lower temperature. Each cold stage in the bulk-material thermoelectric cooler includes a heat source plate, a heat sink plate, a p-type thermoelectric, and a n-type thermoelectric. Moreover, the thin-film thermoelectric cooler can have multiple stages in which each stage contains a heat source plate, a heat sink plate, a p-type super-latticed thermoelectric element, and a n type super-latticed thermoelectric element. By bonding an output heat source plate on the thin-film thermoelectric cooler to an input heat sink plate on the bulk-material thermoelectric cooler, the integration of the thin-film thermoelectric with the bulk-material-based thermoelectric yields a cascade thermoelectric cooler wherein the bulk-material-based thermoelectric cooler cools to 160 K and the thin-film thermoelectric device cools to cryogenic temperatures between 70 and 120 K. Another level of thin-film super-lattice integration can achieve temperatures of 30 K. Alternatively, the integration of a high ZT thin-film superlattice thermoelectric cooler on a multi-staged bulk-material-based thermoelectric cooler can produce a higher performance non-cryogenic cooler. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,620,801 | 17.beta.-amino and hydroxylamino-11.beta.-arylsteroids and their derivatives having agonist or antagonist hormonal properties | September 16, 2003 |
| The invention is directed to a novel class of steroids which exhibit potent antiprogestational activity. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,593,348 | Opiate compounds, methods of making and methods of use | July 15, 2003 |
| The present application relates to novel opioid receptor antagonists and agonists, methods of making these compounds, and methods of use thereof. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,559,159 | Kappa opioid receptor ligands | May 6, 2003 |
| Structurally novel kappa opioid receptor antagonists are provided and the use of these antagonists in treatment of disease states that are ameliorated by binding of the kappa opioid receptor such as heroin or cocaine addictions. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,558,504 | Plasma processing system and method | May 6, 2003 |
| A plasma processing system and method wherein a power source produces a magnetic field and an electric field, and a window disposed between the power source and an interior of a plasma chamber couples the magnetic field into the plasma chamber thereby to couple power inductively into the chamber and based thereon produce a plasma in the plasma chamber. The window can be shaped and dimensioned to control an amount of power capacitively coupled to the plasma chamber by means of the electric field so that the amount of capacitively coupled power is selected in a range from zero to a predetermined amount. Also, a tuned antenna strap having r.f. power applied thereto to produce a standing wave therein can be arranged adjacent the window to couple magnetic field from a current maximum formed in the strap to the interior of the chamber. A desired amount of magnetic field and/or electric field coupling can be produced by arrangement of the chamber window adjacent that portion of the antenna strap exhibiting the desired current/voltage relationship. The system may be formed in a line source configuration, or in a cylindrical source configuration. The window may have slots and/or apertures, the size and shape of which may be variable. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,552,032 | Opiate compounds, methods of making and methods of use | April 22, 2003 |
| The present application relates to novel opioid receptor antagonists and agonists, methods of making these compounds, and methods of use thereof. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,552,295 | Plasma furnace disposal of hazardous wastes | April 22, 2003 |
| A method and apparatus for plasma waste disposal of hazardous waste material, where the hazardous material is volatilized under vacuum inside a containment chamber to produce a pre-processed gas as input to a plasma furnace including a plasma-forming region in which a plasma-forming magnetic field is produced. The pre-processed gas is passed at low pressure and without circumvention through the plasma-forming region and is directly energized to an inductively coupled plasma state such that hazardous waste reactants included in the pre-processed gas are completely dissociated in transit through the plasma-forming region. Preferably, the plasma-forming region is shaped as a vacuum annulus and is dimensioned such that there is no bypass by which hazardous waste reactants in the pre-processed gas can circumvent the plasma-forming region. The plasma furnace is powered by a high frequency power supply outputting power at a fundamental frequency. The power supply contains parasitic power dissipation mechanisms to prevent non-fundamental, parasitic frequencies from destabilizing the fundamental frequency output power. These power loss mechanisms use either distributed resistance or frequency-selective power-loss devices to prevent parasitic oscillations from instantaneously turning on the high frequency power oscillator at non-fundamental frequencies. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,538,010 | Compounds and methods for promoting smoking cessation | March 25, 2003 |
| Compounds and methods for promoting smoking cessation. The compounds may be used to treat a variety of other conditions and disease states. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,531,483 | Cocaine receptor binding ligands | March 11, 2003 |
| The invention relates to novel compounds which show high affinity for cocaine receptors in the brain, particularly dopamine and serotonin transporter sites. The compounds may be used as imaging or pharmaceutical agents, in the diagnosis and treatment of drug addiction, depression, anorexia and neurodegenerative diseases. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,531,481 | Opiate compounds, methods of making and methods of use | March 11, 2003 |
| The present application relates to novel opioid receptor antagonists and agonists, methods of making these compounds, and methods of use thereof. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,505,468 | Cascade cryogenic thermoelectric cooler for cryogenic and room temperature applications | January 14, 2003 |
| A cascade thermoelectric cooler designed to cool to cryogenic temperatures of 30 to 120 K integrates high performance.backslash.high-ZT Bi.sub.x Sb.sub.2-x Te.sub.3 and Bi.sub.2 Te.sub.3-x Se.sub.3 -based super-lattice-structure thin-film thermoelectric devices with a bulk-material based thermoelectric cooler including plural cascaded cold stages with each successive cascaded cold stage able to cool to a progressively lower temperature. Each cold stage in the bulk-material thermoelectric cooler includes a heat source plate, a heat sink plate, a p-type thermoelectric, and a n-type thermoelectric. Moreover, the thin-film thermoelectric cooler can have multiple stages in which each stage contains a heat source plate, a heat sink plate, a p-type super-latticed thermoelectric element, and a n type super-latticed thermoelectric element. By bonding an output heat source plate on the thin-film thermoelectric cooler to an input heat sink plate on the bulk-material thermoelectric cooler, the integration of the thin-film thermoelectric with the bulk-material-based thermoelectric yields a cascade thermoelectric cooler wherein the bulk-material-based thermoelectric cooler cools to 160 K and the thin-film thermoelectric device cools to cryogenic temperatures between 70 and 120 K. Another level of thin-film super-lattice integration can achieve temperatures of 30 K. Alternatively, the integration of a high ZT thin-film superlattice thermoelectric cooler on a multi-staged bulk-material-based thermoelectric cooler can produce a higher performance non-cryogenic cooler. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,502,469 | Portable air sampling apparatus including non-intrusive activity monitor and methods of using same | January 7, 2003 |
| Portable air sampling apparatus and methods are provided for passively and/or intermittently sampling air in the breathing zone of a person over extended periods of time. The presence of airborne contaminants can be monitored, as well. Air sampling system performance can be continuously measured and recorded within a data logger. In addition, physical activity levels of a person wearing a portable air sampling system can be continuously monitored and recorded within the data logger. An input device communicates with the data logger and allows a user to store information about his or her personal activities in the data logger. A receiver in communication with the data logger can receive data from remotely located communications devices, such as a Global Positioning System (GPS) signals. A transmitter in communication with the data logger can transmit data from the data logger to remotely located communications devices. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,485,633 | Process for the demercaptanization of petroleum distillates | November 26, 2002 |
| The demercaptanizaiton of petroleum distillates can be carried out by sorption of the mercaptan with activated carbon and oxidation of the sorbed mercaptan to disulfide at between approximately 20.degree. C. to 55.degree. C. The activated carbon used in the process is commercially readily available. Its surface area typically ranges from between approximately 500 to 1500 m.sup.2 /g and has substantial percentage of the pores in the 10 to 100 Angstrom range. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,479,509 | Method of promoting smoking cessation | November 12, 2002 |
| A method of training a smoker to cease smoking by administering tropane compounds is provided. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,416,735 | Ligands for .alpha.-7 nicotinic acetylcholine receptors based on methyllcaconitine | July 9, 2002 |
| Ligands for nAChRs are provided based on various derivatives of methyllycaconitine (MLA) such as radiolabeled MLA, and MLA containing a fluorimetric marker group and their use in imaging for detection of Alzheimer's and other CNS diseases, and combinatorial assays for detection of compounds having affinity for nAChRs, as well as injectable compositions containing the same and kits for performing the imaging studies. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,410,943 | Light emitting device contact layers having substantially equal spreading resistance and method of manufacture | June 25, 2002 |
| A light emitting device and method of fabricating a light emitting device. The device contains a light emitting junction, such as a pn junction. Contacts (11, 15) to the junction are designed to have substantially the same spreading resistance to produce a substantially uniform voltage across the light emitting junction. This will produce substantially light emission by the junction. The contacts can include contact layers (11, 15) whose spreading resistances are substantially matched by controlling the doping, thickness and/or composition of the layers. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,369,047 | Androgenic steroid compounds and a method of making and using the same | April 9, 2002 |
| An androgenic steroid compound of the formula: ##STR1## wherein: X Y, Z, R.sup.1, R.sup.2, R.sup.3, R.sup.5 and R.sup.6 are as defined herein. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,368,930 | Self aligned symmetric process and device | April 9, 2002 |
| A semiconductor device and method of fabricating the device. An emitter region is formed self centered and self aligned symmetrically with a base region. Using frontside processing techniques, a collector is formed symmetrically self-aligned with the base region and the emitter region. The collector region may be further formed self-centered with the base region using backside processing techniques. The self-aligned and self-centered symmetric structure virtually eliminates parasitic elements in the device significantly improving the device performance. The device is scalable on the order of approximately 0.1 microns. The method also provides reproduceability and repeatability of device characteristics necessary for commercial manufacture of the symmetric device. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,358,492 | Dopamine transporter imaging ligand | March 19, 2002 |
| The 3.alpha. isomer of RTI-55, RTI-352, is an effective in vivo binding ligand that reflects greater selectivity for the dopamine transporter than is observed with RTI-55. In addition, there is also a more rapid achievement of apparent equilibrium in the striatal-to-cerebellar ratio (compared to RTI-55) as the ratio peaks at about 30 min and is maintained for about 20 min thereafter. Such apparent equilibrium is useful in developing an approach to measuring the number of dopamine transporters present in tissues. Moreover, these results indicate that the utilization of 3.alpha. isomers of a variety of 3.beta.-(substituted phenyl)tropanes will result in greater selectivity for dopamine transporters and a more rapid of achievement of apparent equilibrium. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,329,520 | Cocaine receptor binding ligands | December 11, 2001 |
| The invention relates to novel compounds which show high affinity for cocaine receptors in the brain, particularly dopamine and serotonin transporter sites. The compounds may be used as imaging or pharmaceutical agents, in the diagnosis and treatment of drug addiction, depression, anorexia and neurodegenerative diseases or in determining the doses of therapeutic agents that occupy significant numbers of receptors. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,327,918 | Portable air sampling apparatus including non-intrusive activity monitor and methods of using same | December 11, 2001 |
| Portable air sampling apparatus and methods are provided for passively and/or intermittently sampling air in the breathing zone of a person over extended periods of time. The presence of airborne contaminants can be monitored, as well. Air sampling system performance can be continuously measured and recorded within a data logger. In addition, physical activity levels of a person wearing a portable air sampling system can be continuously monitored and recorded within the data logger. An input device communicates with the data logger and allows a user to store information about his or her personal activities in the data logger. A receiver in communication with the data logger can receive data from remotely located communications devices, such as a Global Positioning System (GPS) signals. A transmitter in communication with the data logger can transmit data from the data logger to remotely located communications devices. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,306,793 | Metal sulfide initiators for metal oxide sorbent regeneration | October 23, 2001 |
| A process of regenerating a sulfided sorbent is provided. According to the process of the invention, a substantial portion of the energy necessary to initiate the regeneration reaction is provided by the combustion of a particulate metal sulfide additive. In using the particulate metal sulfide additive, the oxygen-containing gas used to regenerate the sulfided sorbent can be fed to the regeneration zone without heating or at a lower temperature than used in conventional processes wherein the regeneration reaction is initiated only by heating the oxygen-containing gas. The particulate metal sulfide additive is preferably an inexpensive mineral ore such as iron pyrite which does not adversely affect the regeneration or corresponding desulfurization reactions. The invention further includes a sorbent composition comprising the particulate metal sulfide additive in admixture with an active metal oxide sorbent capable of removing one or more sulfur compounds from a sulfur-containing gas stream. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,300,150 | Thin-film thermoelectric device and fabrication method of same | October 9, 2001 |
| A termoelectric device and method for manufacturing the thermoelectric device. The termoelectric device includes at least one deposited film of a thermoelectric material having opposed first and second major surfaces separated by a thickness of the at least one deposited film with the at least one deposited film being patterned to define a plurality of thermoelements arranged in a matrix pattern having rows of alternating conductivity type, a first header having formed thereon a first interconnecting member with the first header mounted on the first major surface of the deposited film such that the first interconnecting member is connected to one side of the plurality of thermoelements and connects adjacent thermoelements of an opposite conductivity type, and a second header having formed thereon a second interconnecting member with the second heads mounted on the second major surface of the deposited film such that the second interconnecting member is connected to an opposite side of said plurality of thermoelements and connects adjacent thermoelements of an opposite conductivity type. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,288,072 | Camptothecin .beta.-alanine esters with topoisomerase I inhibition | September 11, 2001 |
| .beta.-Alanine esters of camptothecin compounds which are effective anti-tumor compounds are disclosed. These compounds inhibit the enzyme topoisomerase I and may alkylate DNA of the associated topoisomerase I-DNA cleavable complex. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,268,375 | 10, 11-difluoromethylenedioxycamptothecin compounds with topoisomerase I inhibition | July 31, 2001 |
| Camptothecin compounds having a C.sub.10 11 O--(CF.sub.2).sub.n O group where n is 1 or 2 are effective anti-tumor compounds. These compounds inhibit the enzyme topoisomerase I and may alkylate DNA of the associated topoisomerase I-DNA cleavable complex. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,262,042 | 17.beta.-amino and hydroxylamino-11.beta.-arylsteroids and their derivatives having agonist or antagonist hormonal properties | July 17, 2001 |
| The invention is directed to a novel class of steroids which exhibit potent antiprogestational activity. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,242,794 | Self-aligned symmetric intrinsic device | June 5, 2001 |
| A semiconductor device and method of fabricating the device. An emitter region is formed self centered and self aligned symmetrically with a base region. Using frontside processing techniques, a collector is formed symmetrically self-aligned with the base region and the emitter region. The collector region may be further formed self-centered with the base region using backside processing techniques. The self-aligned and self-centered symmetric structure virtually eliminates parasitic elements in the device significantly improving the device performance. The device is scalable on the order of approximately 0.1 microns. The method also provides reproduceability and repeatability of device characteristics necessary for commercial manufacture of the symmetric device. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,172,052 | 17.beta.-acyl-17.alpha.-propynyl-11.beta.-arylsteroids and their derivatives having agonist or antagonist hormonal properties | January 9, 2001 |
| The invention is directed to a novel class of 17.beta.-acyl-17.beta.-propynyl steroids which exhibit potent antiprogestational activity. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,123,917 | Method for making cocaine receptor binding ligands and intermediates therefor | September 26, 2000 |
| An improved method for preparation of cocaine receptor binding ligands is provided. The method calls for the preparation of the silylaryl intermediate prepared from phenyl trimethylsilane and a anhydroecgonine methyl ester appropriately substituted. The intermediate is prepared in high purity and can be directly converted to the binding ligand by iodine substitution. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,105,518 | Durable plasma treatment apparatus and method | August 22, 2000 |
| A method and apparatus for treating a work surface, wherein there is provided a chamber having a longitudinal axis and longitudinally extending electrically conductive sidewalls, at least one sidewall having at least one longitudinally extending gap that interrupts a current path through the sidewalls transverse to the longitudinal axis, and wherein the chamber is sealed to allow pressure inside the chamber to be controlled. Also provided is an axially-extending array of current-carrying conductors which at least partially encircle the chamber, are transverse to the longitudinal axis, and establish a magnetic field parallel to the longitudinal axis of the chamber, and a power supply connected to the conductor array and adapted to provide high-frequency current in the conductors to magnetically induce ionization of the gaseous material in the chamber and form a plasma sheath that surrounds and extends along the longitudinal axis and conforms to the sidewalls of the chamber, and wherein the work surface is exposed to the plasma sheath and extends in the direction of the longitudinal axis. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,107,151 | Heterojunction bipolar transistor and method of manufacturing | August 22, 2000 |
| A heterojunction bipolar transistor structure grown with organometallic vapor phase epitaxy (OVMPE) which uses zinc as the base dopant. The HBT structure has eight layers grown on a substrate, including n-type doped first, second, third, fifth, sixth, seventh, and eighth layers and a p-type zinc doped fourth layer. The first layer is a thicker, moderately doped n-type layer compared to the thinner, higher doped n-type second layer. The seventh layer is a thicker, moderately doped n-type layer compared to the thinner, higher doped n-type eighth layer. In addition, some or perhaps all of the layers have a high V/III ratio of 10-100 used to increase the gallium vacancies and reduce the diffusion of zinc from the base layer. Further, annealing of the structure is performed during growth to minimize gallium interstitials and to inhibit the diffusion of zinc. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,105,440 | Portable air sampling systems including non-intrusive activity monitor and methods of using same | August 22, 2000 |
| Portable air sampling systems and methods are provided for intermittently sampling air in the breathing zone of a person over extended periods of time. Air sampling system performance can be continuously measured and recorded within a data logger. In addition, physical activity levels of a person wearing a portable air sampling system can be continuously monitored and recorded within the data logger. Air sampling system performance monitoring includes measuring pressure drop across a filter and measuring temperature of air flowing through the filter. Physical activity levels of a person can be monitored easily and non-intrusively by measuring changes in electrical capacitance of a transducer maintained in close proximity to the person. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,093,707 | 17.beta.-nitro-11.beta.-arylsteroids and their derivatives having agonist or antagonist hormonal properties | July 25, 2000 |
| The invention is directed to a novel class of steroids which exhibit potent antiprogestational activity. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,071,351 | Low temperature chemical vapor deposition and etching apparatus and method | June 6, 2000 |
| An apparatus and method for the growth and etching of materials where a substrate on which a film is being deposited or which is being etched is maintained at a lower temperature than a precursor cracking temperature. The apparatus includes a susceptor with separators, made of an optically transmissive material with low thermal conductivity, such as quartz, upon which the substrates are mounted. The susceptor is heated to a precursor cracking temperature while the substrates are maintained at a lower deposition temperature by the separators. The substrates are heated by black body radiation transmitted through the separators to the substrates. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,043,235 | 11.beta.-aryl-17, 17-spirothiolane-substituted steroids | March 28, 2000 |
| The invention is directed to 11.beta.-aryl-17,17-spirothiolane substituted steroid compounds of formula (I) exhibiting binding to the progestin receptor. ##STR1## Also disclosed are methods of using and process of making the compounds. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,040,313 | Water-soluble esters of camptothecin compounds | March 21, 2000 |
| Non-toxic camptothecin prodrugs are prepared by esterifying the 20-position hydroxyl group of camptothecin derivatives. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,020,328 | 20-keto-11.beta.-arylsteroids and their derivatives having agonist or antagonist hormonal properties | February 1, 2000 |
| The invention is directed to 20-keto-11.beta.-arylsteroids of formula I: ##STR1## wherein R.sup.1, R.sup.6, R.sup.7, R.sup.9, R.sup.12 and X are as defined by the specification. The compounds exhibit progestational and antiprogestational activities. | ||
| Abstract | Patent Details (US PTO) | ||
| 6,015,805 | 17.beta.-nitro-11.beta.-arylisteroids and their derivatives having agonist or antagonist hormonal properties | January 18, 2000 |
| The invention is directed to 11.beta.-arylsteroids of formula II: ##STR1## wherein R.sup.1, R.sup.6, R.sup.8, R.sup.12 and X are as defined by the specification. The compounds exhibit potent antiprogestational activity and are useful in the treatment of fibroids, endometriosis, cervical ripening prior to delivery, hormone replacement therapy and in the control of fertility. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,985,888 | Camptothecin compounds with combined topoisomarase I inhibition and DNA alkylation properties | November 16, 1999 |
| Camptothecin compounds having a --CH.sub.2 --L group are effective anti-tumor compounds. These compounds inhibit the enzyme topoisomerase I and DNA of associated topoisomerase I-DNA complexes. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,972,835 | Fluidizable particulate materials and methods of making same | October 26, 1999 |
| The invention provides fluidizable, substantially spherical particulate material of improved attrition resistance having an average particle size from about 100 to about 400 microns useful as sorbents, catalysts, catalytic supports, specialty ceramics or the like. The particles are prepared by spray drying a slurry comprising inorganic starting materials and an organic binder. Exemplary inorganic starting materials include mixtures of zinc oxide with titanium dioxide, or with iron oxide, alumina or the like. Exemplary organic binders include polyvinyl alcohol, hydroxypropylemethyl cellulose, polyvinyl acetate and the like. The spray dried particles are heat treated at a first temperature wherein organic binder material is removed to thereby provide a porous structure to the particles, and thereafter the particles are calcined at a higher temperature to cause reaction of the inorganic starting materials and to thereby form the final inorganic particulate material. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,962,444 | 17.beta.-nitro-11.beta.-arylsteroids and their derivatives having agonist or antagonist hormonal properties | October 5, 1999 |
| The invention is directed to 17.beta.-nitro-11.beta.-arylsteroids of formula I: ##STR1## wherein R.sup.1, R.sup.6, R.sup.7, R.sup.12 and X are as defined by the specification. The compounds exhibit potent antiprogestational activity and are useful in the treatment of fibroids, endometriosis, cervical ripening prior to delivery, hormone replacement therapy and in the control of fertility. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,959,690 | Method and apparatus for transitions and other special effects in digital motion video | September 28, 1999 |
| A method and apparatus for transition effects in digitally compressed motion video, such video complying with the MPEG-1 standard. Transitions between two frames of video are effectuated by selecting a FROM frame and a TO frame, generating a stream of bidirectionally dependent duplicator frames which vary in their motion vector references to the FROM frame and the TO frame according to a predefined pattern, placing the FROM frame in the past buffer of a decoder, placing the TO frame in the future frame of a decoder, feeding the stream of duplicator frames to the decoder, causing the duplicator frames to be displayed, and beginning normal playback of the video stream containing the TO frame at the TO frame position. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,952,319 | Androgenic steroid compounds and a method of making and using the same | September 14, 1999 |
| An androgenic steroid compound of the formula: ##STR1## wherein: X, Y, Z, R.sup.1, R.sup.2, R.sup.3, R.sup.5 and R.sup.6 are as defined herein. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,952,336 | Hexahydroindenopyridine compounds having antispermatogenic activity | September 14, 1999 |
| Hexahydroindenopyridine compounds having the following formula and relative stereochemistry ##STR1## where R.sup.1 is C.sub.1-6 alkyl; R.sup.2 is hydrogen or C.sub.1-6 alkyl; R.sup.3 is carboxyl or a group which is metabolized to a carboxyl group under mammalian physiological conditions; R.sup.4 is halogen; mixtures of said compound and acid addition salts thereof exhibit potent antispermatogenic activity and are useful in a method of inhibiting spermatogenesis in mammals. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,935,953 | Methods for controlling invertebrate pests using cocaine receptor binding ligands | August 10, 1999 |
| The invention relates to a method of controlling an invertebrate pest, comprising contacting the pest with a pest-controlling amount of an agent having substantial inhibitory activity toward a phenylethanolamine reuptake transporter as determined by radioactive octopamine reuptake inhibition assay is disclosed. Compositions comprising compounds capable of inhibiting the octopamine reuptake transporter include cocaine analogs. A process for inhibiting the feeding of an invertebrate pest comprising contacting said pest with a pest-controlling amount of an agent having substantial inhibitory activity toward a phenylethanolamine reuptake transporter as determined by radioactive octopamine reuptake inhibition assay, with the proviso that said agent is not cocaine. A process for delaying the maturation of a juvenile invertebrate by contacting it with an inhibitory amount of a phenylethanolamine reuptake transporter blocker is also disclosed. A radioactive phenylethanolamine reuptake inhibition assay for determining whether a given compound is an inhibitor of octopamine neuronal transport is also disclosed. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,932,588 | Camptothecin compounds with combined topoisomerase I inhibition and DNA alkylation properties | August 3, 1999 |
| Camptothecin compounds having a --CH.sub.2 --L group are effective anti-tumor compounds. These compounds inhibit the enzyme topoisomerase I and DNA of associated topoisomerase I-DNA complexes. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,928,980 | Attrition resistant catalysts and sorbents based on heavy metal poisoned FCC catalysts | July 27, 1999 |
| A heavy metal poisoned, spent FCC catalyst is treated by chemically impregnating the poisoned catalyst with a new catalytic metal or metal salt to provide an attrition resistant catalyst or sorbent for a different catalytic or absorption processes, such as catalysts for Fischer-Tropsh Synthesis, and sorbents for removal of sulfur gasses from fuel gases and flue-gases. The heavy metal contaminated FCC catalyst is directly used as a support for preparing catalysts having new catalytic properties and sorbents having new sorbent properties, without removing or "passivating" the heavy metals on the spent FCC catalyst as an intermediate step. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,916,896 | Water-soluble esters of camptothecin compounds | June 29, 1999 |
| Non-toxic camptothecin prodrugs are prepared by esterifying the 20-position hydroxyl group of camptothecin derivatives. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,914,288 | Metal sulfide initiators for metal oxide sorbent regeneration | June 22, 1999 |
| A process of regenerating a sulfided sorbent is provided. According to the process of the invention, a substantial portion of the energy necessary to initiate the regeneration reaction is provided by the combustion of a particulate metal sulfide additive. In using the particulate metal sulfide additive, the oxygen-containing gas used to regenerate the sulfided sorbent can be fed to the regeneration zone without heating or at a lower temperature than used in conventional processes wherein the regeneration reaction is initiated only by heating the oxygen-containing. The particulate metal sulfide additive is preferably an inexpensive mineral ore such as iron pyrite which does not adversely affect the regeneration or corresponding desulfurization reactions. The invention further includes a sorbent composition comprising the particulate metal sulfide additive in admixture with an active metal oxide sorbent capable of removing one or more sulfur compounds from a sulfur-containing gas stream. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,908,565 | Line plasma vapor phase deposition apparatus and method | June 1, 1999 |
| A line plasma source (20) comprises a plasma chamber (30) configured so that plasma (32) is situated remotely and on-edge with respect to a polycrystalline silicon surface (20S) to be treated, thereby preventing damage to the surface, facilitating treatment of large substrates, and permitting low temperature operation. Active species exit the plasma chamber through a long narrow ("line") outlet aperture (36) in the plasma chamber to a reaction zone (W) whereat the active species react with a reaction gas on the polycrystalline silicon surface (e.g., to form a deposited thin film). The polycrystalline silicon surface is heated to a low temperature below 6000.degree. C. Hydrogen is removed from the reactive surface in the low temperature line plasma source by a chemical displacement reaction facilitated by choice of dominant active species (singlet delta state of molecular oxygen). Reaction by-products including hydrogen are removed by an exhaust system (100) comprising long narrow exhaust inlet apertures (114L,114R) extending adjacent and parallel to the outlet aperture of the plasma chamber. An ionizing electric field is coupled to the plasma across a smallest dimension of the plasma, resulting in uniform production of active species and accordingly uniform quality of the thin film. The polycrystalline silicon surface to be treated is translated with respect to the plasma line source in a direction perpendicular to the outlet aperture of the plasma line source for integrating thin film quality in the direction of translation (22). | ||
| Abstract | Patent Details (US PTO) | ||
| 5,874,014 | Durable plasma treatment apparatus and method | February 23, 1999 |
| A method and apparatus for treating a work surface, wherein there is provided a chamber having a longitudinal axis and longitudinally extending electrically conductive sidewalls, at least one sidewall having at least one longitudinally extending gap that interrupts a current path through the sidewalls transverse to the longitudinal axis, and wherein the chamber is sealed to allow pressure inside the chamber to be controlled. Also provided is an axially-extending array of current-carrying conductors which at least partially encircle the chamber, are transverse to the longitudinal axis, and establish a magnetic field parallel to the longitudinal axis of the chamber, and a power supply connected to the conductor array and adapted to provide high-frequency current in the conductors to magnetically induce ionization of the gaseous material in the chamber and form a plasma sheath that surrounds and extends along the longitudinal axis and conforms to the sidewalls of the chamber, and wherein the work surface is exposed to the plasma sheath and extends in the direction of the longitudinal axis. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,831,095 | Synthesis of 5-aminocarbonyl-5H-dibenzo[a,d]cyclohepten-5,10-imine | November 3, 1998 |
| A powerful new anti-convulsant and anti-ischemic pharmaceutical, 5-aminocarbonyl-5H-dibenzo[a,d]cycloheptene-5,10-imine is prepared according to a novel synthesis which converts the starting material, commercially available dibenzosubernone to ADCI without the use of chromatographic purification, hazardous reagents or extreme conditions. The starting material is converted to the corresponding imine through ammonia exposure, and directly converted with acetone cyanohydrin in the presence of sodium cyanide to a 5-amino, 5-cyanocycloheptene intermediate. The intermediate is cyclized using bromine, followed by a reduction of the bromine-carbon bond using sodium cyanoborohydride. The target compound is obtained through selective hydrolysis. An overall yield of 46 percent or better is obtained. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,800,620 | Plasma treatment apparatus | September 1, 1998 |
| A method and apparatus for generating plasmas adapted for chemical vapor deposition, etching and other operations, and in particular to the deposition of large-area diamond films, wherein a chamber defined by sidewalls surrounding a longitudinal axis is encircled by an axially-extending array of current-carrying conductors that are substantially transverse to the longitudinal axis of the chamber, and a gaseous material is provided in the chamber. A high-frequency current is produced in the conductors to magnetically induce ionization of the gaseous material in the chamber and form a plasma sheath that surrounds and extends along the longitudinal axis and conforms to the sidewalls of the chamber. A work surface extending in the direction of the longitudinal axis of the chamber is positioned adjacent a sidewall, exposed to the plasma sheath and treated by the plasma. Preferably, the ratio of the width to the height of the chamber is 10:1 or larger so that the chamber includes a large area planar surface adjacent the plasma sheath and adjacent to which a large area substrate or a plurality of substrates is arranged, whereby large area treatment, such as diamond deposition, can be performed. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,798,088 | Method for producing elemental sulfur from sulfur-containing gases | August 25, 1998 |
| A method for producing elemental sulfur and reduced/oxidized sulfur compounds from sulfur containing gases. The method comprises mixing a primary gas stream of sulfur-containing gases with a secondary gas stream to produce a combined gas stream having a preselected stoichiometry and contacting the combined gas stream with a catalyst at a pressure of 7 to 100 atmospheres and a temperature of 540.degree. to 700.degree. C. The catalyst is selected from the group consisting of silica, titania, alumina, sodium/alumina, zinc titanate, alumina or titania promoted with transition metals nickel, cobalt, molybdenum, tungsten, alloys and mixtures thereof and mixture of such catalysts. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,780,880 | High injection bipolar transistor | July 14, 1998 |
| An optoelectronic semiconductor device using stimulated emission and absorption to achieve the functions of detection, modulation, generation and/or amplification of light. In one embodiment, the device includes a waveguide heterojunction bipolar transistor (HBT) biased in the active mode where the minority carrier concentration in the base is designed with bandgap engineering to optimize optical gain in this region. This HBT configuration allows optical modulation at considerably higher frequencies and/or with improved efficiency compared to the prior art, and is particularly suited to the fabrication of direct or external modulated wideband fiber optic links. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,747,503 | Selective inhibitors of biogenic amine transporters | May 5, 1998 |
| The present invention provides a compound having the structure: ##STR1## wherein X, Y, and Z are independently H, Cl, Br, F, OCH.sub.3, I, or an alkyl group having 1 to 6 carbon atoms; and R is ##STR2## wherein n is 0 to 6, X' and Y' are independently H, Cl, F, CH.sub.3, C.sub.2 H.sub.5, C.sub.3 H.sub.7, C.sub.4 H.sub.9, OCH.sub.3, OH, CF.sub.3, OCF.sub.3, NO.sub.2, NH.sub.2, N(CH.sub.3).sub.2, NHCOCH.sub.3, NCS, NHCOCH.sub.2 Br, or N.sub.3, and (CH.sub.2).sub.n, if present, may be substituted with OH, OCH.sub.3, or an alkyl or alkenyl group having 1 to 3 carbon atoms. The present invention also provides a pharmaceutical composition comprising the compound above and a pharmaceutically acceptable carrier. The present invention further provides a method for treating a disease characterized by a dopamine deficiency which comprises administering to a subject in need of such treatment an amount of the pharmaceutical composition above effective to treat the disease. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,736,123 | Cocaine receptor binding ligands | April 7, 1998 |
| Novel compounds useful as intermediates in the synthesis of compounds having high affinity for specific cocaine receptors in the brain have the formula ##STR1## wherein R is (CH.sub.2).sub.n CH.sub.2 Y, and wherein Y is H or F, X is a pharmaceutically acceptable anion, and wherein Sn (R.sup.1, R.sup.2, R.sup.3) is ortho, meta or para and wherein R.sup.1, R.sup.2, R.sup.3 are independently alkyl of 1-6 carbon atoms and n is an integer of 0-5. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,714,431 | Zinc titanate sorbents | February 3, 1998 |
| The present invention provides a zinc titanate sorbent material useful in desulfurization applications. The zinc titanate material is in the form of generally spherical particles of substantially uniform chemical distribution. The sorbent material is capable of absorbing sulfur compounds from a gaseous feed in an amount of at least about 15 weight percent based on the weight of the sorbent. The sorbent material is prepared by a process including: (a) forming a zinc oxide/titanium dioxide dry blend, (b) preparing a substantially uniform aqueous slurry comprising the zinc oxide/titanium dioxide dry blend, organic binder, and at least about 1 weight percent inorganic binder based on the solids weight of the slurry, (c) spray drying the slurry to produce substantially spherical particles, and (d) calcining the particles at a temperature of between about 750.degree. C. to about 950.degree. C. The dry blend is formed by mixing between about 0.5 to about 2 parts zinc oxide having a median particle size of less than about 0.5 .mu., and about 1 part titanium dioxide having a median particle size of less than about 1 .mu.. The slurry contains substantially no free silica and may be prepared by the process including (1) preparing an aqueous solution of organic binder, (2) adding the dry blend to the aqueous solution of organic binder, and (3) adding the inorganic binder to the solution of organic binder, and blend. Additional reagents, such as a surfactant, may also be incorporated into the sorbent material. The present invention also provides a process for desulfurizing a gaseous stream. The process includes passing a gaseous stream through a reactor containing an attrition resistant zinc titanate sorbent material of the present invention. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,646,159 | Water-soluble esters of camptothecin compounds | July 8, 1997 |
| Non-toxic camptothecin prodrugs are prepared by esterifying the 20-position hydroxyl group of camptothecin derivatives. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,643,639 | Plasma treatment method for treatment of a large-area work surface apparatus and methods | July 1, 1997 |
| A method and apparatus for generating plasmas adapted for chemical vapor deposition, etching and other operations, and in particular to the deposition of large-area diamond films, wherein a chamber defined by sidewalls surrounding a longitudinal axis is encircled by an axially-extending array of current-carrying conductors that are substantially transverse to the longitudinal axis of the chamber, and a gaseous material is provided in the chamber. A high-frequency current is produced in the conductors to magnetically induce ionization of the gaseous material in the chamber and form a plasma sheath that surrounds and extends along the longitudinal axis and conforms to the sidewalls of the chamber. A work surface extending in the direction of the longitudinal axis of the chamber is positioned adjacent a sidewall, exposed to the plasma sheath and treated by the plasma. Preferably, the ratio of the width to the height of the chamber is 10:1 or larger so that the chamber includes a large area planar surface adjacent the plasma sheath and adjacent to which a large area substrate or a plurality of substrates is arranged, whereby large area treatment, such as diamond deposition, can be performed. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,637,653 | Polymer blend materials composed of an aromatic polyamide and a soluble polyamide | June 10, 1997 |
| Polymer blend materials composed of an aromatic polyamide and flexible polyamide wherein the aromatic polyamide molecules are uniformly dispersed in a matrix of the flexible polyamide which are produced by first blending the flexible polyamide and monomer(s) for the aromatic polyamide in a solvent, then next polymerizing the monomer(s) in the presence of a phosphite compound, resulting in a transparent gel product capable of being fabricated into useful shaped articles without causing marked phase separation observed in polymer blend materials obtained by conventional coagulation method. The in situ formed aromatic polyamide is uniformly dispersed in the flexible polyamide matrix even in fabricated forms, giving improved transparency over the starting flexible polyamide and improved resistance toward chemicals such as acids, especially after heat treatment. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,614,529 | Inhibition of plasmodia parasites by camptothecin compounds | March 25, 1997 |
| Camptothecin compounds are effective inhibitors of plasmodia growth and are useful in treating plasmodia infections in livestock, other domestic animals and humans. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,609,736 | Methods and apparatus for controlling toxic compounds using catalysis-assisted non-thermal plasma | March 11, 1997 |
| The present invention provides methods and apparatus for decomposing toxic compounds so that reaction by-products produced thereby are selectively reduced. A method generally comprises: introducing a carrier gas, having a toxic compound entrained therein, into a packed-bed of ferroelectric pellets; and polarizing the pellets to produce a plasma which decomposes the toxic compound. The pellets are coated with a catalyst selected to react with by-products of the decomposition of the toxic compound and thereby produce non-toxic compounds. An apparatus for decomposing toxic compounds and selectively reducing by-products, according to the present invention, comprises: a vessel having an internal passageway therethrough; a packed-bed of pellets coated with at least one catalyst; means for producing a plasma within the packed-bed of pellets; and carrier gas flow means in fluid communication with the internal passageway for causing a carrier gas entrained with toxic compounds to flow through the packed-bed of pellets. The present invention also discloses methods and apparatus wherein a pulsed corona reactor having a catalyst coating on a portion thereof is utilized to decompose toxic compounds. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,585,292 | Method of fabricating a thin film transistor | December 17, 1996 |
| A thin film transistor comprises an insulator interposed between a gate electrode and a polycrystalline silicon semiconductor layer, with the polycrystalline silicon semiconductor layer having a source region and a drain region with a channel between the source region and the drain region. The insulator comprises an ONO structure having an interfacial oxide layer in contact with the polycrystalline silicon semiconductor layer, a cap oxide layer in contact with the gate electrode, and a nitride layer interposed between the interfacial oxide layer and the nitride layer. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,574,060 | Selective inhibitors of biogenic amine transporters | November 12, 1996 |
| The present invention provides a compound having the structure: ##STR1## wherein X, Y, and Z are independently H, Cl, Br, F, OCH.sub.3, I, or an alkyl group having 1 to 6 carbon atoms; and R is ##STR2## wherein n is 0 to 6, X' and Y' are independently H, Cl, F, CH.sub.3, C.sub.2 H.sub.5, C.sub.3 H.sub.7, C.sub.4 H.sub.9, OCH.sub.3, OH, CF.sub.3, OCF.sub.3, NO.sub.2, NH.sub.2, N(CH.sub.3).sub.2, NHCOCH.sub.3, NCS, NHCOCH.sub.2 Br, or N.sub.3, and (CH.sub.2).sub.n, if present, may be substituted with OH, OCH.sub.3, or an alkyl or alkenyl group having 1 to 3 carbon atoms. The present invention also provides a pharmaceutical composition comprising the compound above and a pharmaceutically acceptable carrier. The present invention further provides a method for treating a disease characterized by a dopamine deficiency which comprises administering to a subject in need of such treatment an amount of the pharmaceutical composition above effective to treat the disease. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,496,953 | Cocaine receptor binding ligands | March 5, 1996 |
| Novel compounds show high affinity for specific cocaine receptors in the brain, particularly dopamine transporter sites, and have the formula ##STR1## Wherein Y=CONRR.sub.2, R.sub.1 =hydrogen, C.sub.1-5 alkyl, X=H, C.sub.1-6 alkyl, C.sub.3-8 cycloalkyl, C.sub.1-4 alkoxy, C.sub.1-6 alkynyl, halogen, amino, acylamido, R and R.sup.2 may be saturated or unsaturated substituents of 1-6 carbon atoms, aromatic, or combine to form pyrrolidinyl, morpholinyl or piperidinyl moieties, and Z=H, I, Br, Cl, F, CN, CF.sub.3 NO.sub.2, N.sub.3, OR.sub.1, CO.sub.2 NH.sub.2, CO.sub.2 R.sub.1, C.sub.1-6 alkyl, NR.sub.4 R.sub.5, NHCOF.sub.5, NHCO.sub.2 R.sub.6, wherein R.sub.4 -R.sub.6 are each C.sub.1-6 alkyl. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,496,830 | Inhibition of hemoflagellates by camptothecin compounds | March 5, 1996 |
| Camptothecin compounds are effective inhibitors of hemoflagellate growth and are useful in treating leishmaniasis and trypanosomiasis in livestock, other domestic animals and humans. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,480,686 | Process and apparatus for chemical vapor deposition of diamond films using water-based plasma discharges | January 2, 1996 |
| A chemical vapor deposition (CVD) process and apparatus for the growth of diamond films using vapor mixtures of selected compounds having desired moieties, specifically precursors that provide carbon and etchant species that remove graphite. The process involves two steps. In the first step, feedstock gas enters a conversion zone. In the second step, by-products from the conversion zone proceed to an atomization zone where diamond is produced. In a preferred embodiment a feedstock gas phase mixture including at least 20% water which provides the etchant species is reacted with an alcohol which provides the requisite carbon precursor at low temperature (55.degree.-1100.degree. C.) and low pressure (0.1 to 100 Torr), preferably in the presence of an organic acid (acetic acid) which contributes etchant species reactant. In the reaction process, the feedstock gas mixture is converted to H.sub.2, CO, C.sub.2 H.sub.2, no O.sub.2, with some residual water. Oxygen formerly on the water is transferred to CO. Hence, an etchant species (H.sub.2 O, OH, O) is replaced in the reactor by CO, a growth species and prevents undesirous consumption of diamond (the net-product). In a preferred embodiment, the apparatus assures conversion by preventing gas circumvention of the conversion zone prior to dissociation in the hydrogen atomization zone to produce the necessary atomic hydrogen for diamond growth. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,472,550 | Method and apparatus for protecting a substrate surface from contamination using the photophoretic effect | December 5, 1995 |
| An apparatus for processing a substrate surface in a process chamber wherein during chemical or physical altering of the substrate surface a laser beam is projected inside the processing chamber and along a trajectory which does not contact the substrate surface in order to capture particles by means of the photophoretic effect, particles which would otherwise impinge upon and contaminate the substrate surface. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,439,513 | Device for focussing particles suspended in a gas stream | August 8, 1995 |
| A device for controlling the motion of particles suspended in a gas stream is provided, including a pipe, through which at least a fraction of the gas stream flows, a source of AC voltage, a source of DC voltage, and a plurality of electrode sets positioned within the pipe in series, generating an inhomogeneous electric field to cause the particles suspended in the gas stream to concentrate into a narrow axial region in the center of the pipe. Each electrode set includes a first pair of opposed hyperboloidally shaped electrodes connected to the AC voltage source and a second pair of opposed hyperboloidally shaped electrodes connected to the DC voltage. The first and second pairs of opposed electrodes are positioned at spaced apart intervals around the circumference of the pipe to define an opening through which at least a fraction of the gas stream flows. The electrode sets are positioned within the pipe in series such that the gas stream flows through the openings defined by each successive electrode set. The spaced apart distance between the electrodes of each successive electrode set is decreased to reduce the size of the openings, causing the particles suspended in the gas stream to focus or concentrate along successively narrower axial regions in the center of the pipe. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,436,243 | Aminoanthraquinone derivatives to combat multidrug resistance | July 25, 1995 |
| Potentiating agents inhibit the development of multidrug resistance, reduce drug-resistance in drug-resistant tumors, or sensitize tumors to antineoplastic drugs, thereby potentiating the effect of antineoplastic agents. The potentiating agents are aminoanthraquinones, preferably 1,4-bis(N-substituted) amino anthraquinones, and pharmaceutically acceptable salts thereof. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,418,018 | Chemical vapor deposition of diamond films using water-based plasma discharges | May 23, 1995 |
| A chemical vapor deposition (CVD) technique (process and apparatus) for the growth of diamond films using vapor mixtures of selected compounds having desired moieties, specifically precursors that provide carbon and etchant species that remove graphite disclosed. The selected compounds are reacted in a plasma created by a confined rf discharge to produce diamond films on a diamond or a non-diamond substrate. In a preferred embodiment a gas phase mixture including at least 20% water which provides the etchant species is reacted with an alcohol which provides the requisite carbon precursor at low temperature (300.degree.-650.degree. C.) and low pressure (0.1 to 10 Torr), preferably in the presence of an organic acid (acetic acid) which contributes etchant species reactant. In the preferred embodiment the volumetric mixtures have typically been 40-80% water and 60-20% alcohol. The gaseous mixture of H.sub.2 O and alcohol is dissociated to produce H, OH, and carbon radicals. Both OH and atomic H are capable of etching graphite from the depositing carbon layer. The selected compounds are reacted in a CVD apparatus in which a confined rf discharge is used to create an electric discharge or plasma. The plasma is confined between an inductive rf coil via transformer isolation from the chamber ground. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,413,779 | Cocaine receptor binding ligands | May 9, 1995 |
| 3.beta.-[4-iodophenyl]-tropan-2.beta.-carboxylic acid methyl ester tartrate is a high affinity binding ligand for cocaine receptors in mammalian brains. It and its congeners may be employed for imaging and other brain scanning techniques that allow the determination of the presence of cocaine receptors, such as dopamine and serotonin transporters and the like. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,401,747 | Alkyl camptothecin compounds as potent inhibitors of human colorectal cancer | March 28, 1995 |
| A method for synthesizing camptothecin and camptothecin analogs using a novel hydroxyl-containing tricyclic intermediate and the camptothecin analogs produced by the process. The camptothecin analogs are effective inhibitors of topoisomerase. I and show antileukemic and anti-tumor activity. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,380,848 | Cocaine receptor binding ligands | January 10, 1995 |
| Novel compounds show high affinity for specific cocaine receptors in the brain, particularly dopamine transporter sites, and have the formula ##STR1## Wherein Y=CH.sub.2 R.sub.3, CO.sub.2 R.sub.2 or ##STR2## R.sub.1 =hydrogen, C.sub.1-5 alkyl, R.sub.2 =hydrogen, C.sub.1-6 alkyl, C.sub.3-8 cycloalkyl, C.sub.1-4 alkoxy, C.sub.1-6 alkynyl, halogen or amine, R.sub.3 =OH, hydrogen, C.sub.1-6 alkyl, C.sub.3-8 cycloalkyl, C.sub.1-4 alkoxy, Cl Br, I, CN, NH.sub.2, NHC.sub.1-6 alkyl, NC.sub.1-6 alkyl, OCOC.sub.1-6 alkyl, OCOC.sub.1-3 alkylaryl, A=S, 0 or NH X=H, C.sub.1-6 alkyl, C.sub.3-8 cycloalkyl, C.sub.1-4 alkoxy, C.sub.1-6 alkynyl, halogen, amino, acylamido, and Z=H, I, Br, Cl, F, CN, CF.sub.3 NO.sub.2, N.sub.3, OR.sub.1, CO.sub.2 NH.sub.2, CO.sub.2 R.sub.1, C.sub.1-6 alkyl , NR.sub.4 R.sub.5, NHCOR.sub.5, NHCO.sub.2 R.sub.6, wherein R.sub.4 -R.sub.6 are each C.sub.1-6 alkyl. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,366,717 | Method for producing elemental sulfur from sulfur-containing gases | November 22, 1994 |
| A method for producing elemental sulfur and reduced/oxidized sulfur compounds from sulfur containing gases. The method comprises mixing a primary gas stream of sulfur-containing gases with a secondary gas stream to produce a combined gas stream having a preselected stoichiometry and contacting the combined gas stream with a sorbent/catalyst. The sorbent/catalyst is selected form the group consisting of silica, alumina, and other Claus-type catalysts, sodium/alumina, zinc ferrite, zinc titanate, and other mixed metal oxides, and mixtures thereof. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,366,559 | Method for protecting a substrate surface from contamination using the photophoretic effect | November 22, 1994 |
| A method for processing a substrate surface in a process chamber wherein during chemical or physical altering of the substrate surface a laser beam is projected inside the processing chamber and along a trajectory which does not contact the substrate surface in order to capture particles by means of the photophoretic effect, particles which would otherwise impinge upon and contaminate the substrate surface. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,364,858 | Camptothecin analogs as potent inhibitors of topoisomerase I | November 15, 1994 |
| A method for synthesizing camptothecin and camptothecin analogs using a novel hydroxyl-containing tricyclic intermediate and the camptothecin analogs produced by the process. The camptothecin analogs are effective inhibitors of topoisomerase.I and show antileukemic and anti-tumor activity. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,340,817 | Method of treating tumors with anti-tumor effective camptothecin compounds | August 23, 1994 |
| A camptothecin analog having the structure shown below: ##STR1## where Z is H or C.sub.1-8 alkyl and R is NO.sub.2, NH.sub.2, N.sub.3, hydrogen, halogen, COOH, OH, O-C.sub.1-3 alkyl, SH, S-C.sub.1-3 alkyl, CN, CH.sub.2 NH.sub.2, NH-C.sub.1-3 alkyl, CH.sub.2 -NH-C.sub.1-3 alkyl, N(C.sub.1-3 alkyl).sub.2, CH.sub.2 N(C.sub.1-3 alkyl).sub.2, O-, NH- or S-CH.sub.2 CH.sub.2 N(CH.sub.2 CH.sub.2 OH).sub.2, O-, NH- or S- CH.sub.2 CH.sub.2 CH.sub.2 N(CH.sub.2 CH.sub.2 OH).sub.2, O-, NH- or S-CH.sub.2 CH.sub.2 N(CH.sub.2 CH.sub.2 CH.sub.2 OH).sub.2, O-, NH- or S-CH.sub.2 CH.sub.2 CH.sub.2 N(CH.sub.2 CH.sub.2 OH.sub.2).sub.2, O-, NH- or S-CH.sub.2 CH.sub.2 N(C.sub.1-3 alkyl).sub.2, O-, NH- or S-CH.sub.2 CH.sub.2 CH.sub.2 N(C.sub.1-3 alkyl).sub.2, CHO, C.sub.1-3 alkyl or NHCOCHR.sup.1 NR.sup.2 R.sup.3, where R.sup.1 is the side-chain of an .alpha.-amino acid and R.sup.2 and R.sup.3, independently are hydrogen or a lower alkyl group or R.sup.3 is a peptide unit containing 1-3 amino acid units bonded to the nitrogen through a peptide bond; NHCO-C.sub.2-8 -alkylene-X or NHCO-C.sub.2-8 -alkenylene-X, where X is COOH; CONR.sup.2 -(CH.sub.2).sub.n -NR.sup.2 R.sup.3, where n=1-10 and R.sup.2 and R.sup.3 are as defined above; NHCO-B-(CH.sub.2).sub.n-NR.sup.2 R.sup.3, where B=oxygen or NH, or ##STR2## where m+y=3-6, and salts thereof. The campothecin compounds inhibit the enzyme topisomerase I and are useful in treating tumors and leukemia. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,319,084 | Hexahydroindenopyridine compounds having antispermatogenic activity | June 7, 1994 |
| Hexahydroindenopyridine compounds having the following formula and relative stereochemistry ##STR1## where R.sup.1 is C.sub.1-6 alkyl, R.sup.2 is hydrogen or C.sub.1-6 alkyl and R.sup.3 is carboxyl or a group which is metabolized to a carboxyl group under mammalian physiological conditions exhibit potent antispermatogenic activity and are useful in a method of inhibiting spermatogenesis in mammals. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,318,916 | Symmetric self-aligned processing | June 7, 1994 |
| A method of manufacturing a semiconductor device using simplified processing and eliminating and/or minimizing the extrinsic parasitic elements of the device. The method is particularly suited for manufacturing heterojunction bipolar transistors where the extrinsic parasitic base resistance and the extrinsic parasitic base-collector and base-emitter capacitances can be virtually eliminated and the base contact resistance can be greatly reduced. The method includes formming symmetric emitter and collector portions using front and backside processing of the wafer, respectively. The symmetric emitter and collector virtually eliminates the extrinsic collector and emitter regions of the device thereby virtually eliminating the extrinsic base-collector and base-emitter capacitance. The extrinsic base contact region may also be increased to minimize the base contact resistance without increasing parasitic capacitive elements of the device. Self-aligned processing features are also included to form self-aligned contacts to the base layer thereby virtually eliminating the extrinsic base resistance. The method may include building up the collector and emitter contacts to separate the emitter and collector interconnections from the base layer to avoid increasing the emitter-base and collector-base extrinsic parasitic capacitances and to minimize associated resistances and inductances. The method may further include forming etch stop layers to facilitate removing of the substrate to perform the backside processing and to accurately etch through the collector layer without etching the base layer. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,298,499 | S-2-(substituted ethylamino)ethyl phosphorothioates | March 29, 1994 |
| Substituted phosphorothioate derivatives and pharmaceutical compositions thereof as potential antiradiation agents are disclosed. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,272,095 | Method of manufacturing heterojunction transistors with self-aligned metal contacts | December 21, 1993 |
| A method of manufacturing heterojunction transistors having self-aligned contacts. In manufacturing a heterojunction bipolar transistor, a collector and a base layer are deposited on a substrate. A masking layer is deposited on the base layer and selectively etched to form an aperture therein, exposing the base layer. An emitter having a mesa structure is grown epitaxially on the exposed base layer to produce lateral overhang portions. The overhang portions may be formed by continuing the epitaxial growth to form lateral overgrowth portions overlapping the masking material. The masking layer is removed and self-aligned contacts are formed to the base and emitter regions using the lateral overhang portions which provide separation between the emitter structure and the contacts to the base layer. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,254,516 | Fluidizable zinc titanate materials with high chemical reactivity and attrition resistance | October 19, 1993 |
| Highly durable and chemically reactive zinc titanate materials are prepared in a particle size range of 50 to 400 .mu.m suitable for a fluidized-bed reactor for removing reduced sulfur species in a gaseous form by granulating a mixture of fine zinc oxide and titanium oxide with inorganic and organic binders and by optional additions of small amounts of activators such as CoO and MoO.sub.3 ; and then indurating it at 800.degree. to 900.degree. C. for a time sufficient to produce attrition-resistant granules. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,244,903 | Camptothecin analogs as potent inhibitors of topoisomerase I | September 14, 1993 |
| A method for synthesizing camptothecin analogs using a novel hydroxyl-containing tricyclic intermediate and the camptothecin analogs produced by the process. The camptothecin analogs are effective inhibitors of topoisomerase. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,229,171 | Apparatus and method for uniformly coating a substrate in an evacuable chamber | July 20, 1993 |
| An apparatus and method including a droplet coating generator for generating a stream of electrically charged coating droplets within an evacuable chamber towards a substrate positioned within the evacuable chamber. A piezoelectric vibrator and orifice plate coupled thereto generate the stream of coating droplets. The coating droplets are urged to move in a sweeping motion across the substrate by at least one pair of opposing spaced apart electrodes powered by an electrical power supply. A uniform coating is thus produced while the evacuable chamber is maintained at subatmospheric pressure as required during typical semiconductor processing. Multiple applications of a photoresist coating may be applied by the coating apparatus without requiring that the evacuable chamber be repeatedly vented and pumped down to subatmospheric pressure. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,227,380 | Pharmaceutical compositions and methods employing camptothecins | July 13, 1993 |
| A method for synthesizing camptothecin and camptothecin analogs using a novel hydroxyl-containing tricyclic intermediate and the camptothecin analogs produced by the process. The camptothecin analogs are effective inhibitors of topoisomerase I and show antileukemic and anti-tumor activity. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,225,404 | Methods of treating colon tumors with tumor-inhibiting camptothecin compounds | July 6, 1993 |
| The present invention provides methods of treating malignant colon and colo-rectal cancer in mammals, by reducing or inhibiting or retarding such colon cancer tumors in mammals. These methods employ the administration of a tumor-inhibiting or reducing camptothecin compound, e.g., 9-amino-20(RS)-camptothecin, 10,11-methylenedioxy-20(RS)-camptothecin, and the sodium salt of 10,11-methylenedioxy-20(RS)-camptothecin, or a combination thereof. Also provided are pharmaceutical formulations. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,180,722 | 10,11-methylenedioxy-20(RS)-camptothecin and 10,11-methylenedioxy-20(S)-camptothecin analogs | January 19, 1993 |
| A camptothecin analog having the structure shown below: ##STR1## where Z is H or C.sub.1-8 alkyl and R is NO.sub.2, NH.sub.2, N.sub.3, hydrogen, halogen, COOH, OH, O--C.sub.1-3 alkyl, SH, S--C.sub.1-3 alkyl, CN, CH.sub.2 NH.sub.2, NH--C.sub.1-3 alkyl, CH.sub.2 --NH--C.sub.1-3 alkyl, N(C.sub.1-3 alkyl).sub.2, CH.sub.2 N(C.sub.1-3 alkyl).sub.2, O--, NH--, or S--CH.sub.2 CH.sub.2 N(CH.sub.2 CH.sub.2 OH).sub.2, O--, NH-- or S-- CH.sub.2 CH.sub.2 CH.sub.2 N(CH.sub.2 CH.sub.2 OH).sub.2, O--, NH-- or S--CH.sub.2 CH.sub.2 N(CH.sub.2 CH.sub.2 CH.sub.2 OH).sub.2, O--, NH-- or S--CH.sub.2 CH.sub.2 CH.sub.2 N(CH.sub.2 CH.sub.2 CH.sub.2 OH.sub.2).sub.2, O--, NH-- or S--CH.sub.2 CH.sub.2 N(C.sub.1-3 alkyl).sub.2, O--, NH-- or S--CH.sub.2 CH.sub.2 CH.sub.2 N(C.sub.1-3 alkyl).sub.2, CHO, C.sub.1-3 alkyl or NHCOCHR.sup.1 NR.sup.2 R.sup.3, where R.sup.1 is the side-chain of an .alpha.-amino acid and R.sup.2 and R.sup.3, independently are hydrogen or a lower alkyl group or R.sup.3 is a peptide unit containing 1-3 amino acid units bonded to the nitrogen through a peptide bond; NHCO--C.sub.2-8 -alkylene--X or NHCO--C.sub.2-8 -alkenylene--X, where X is COOH; CONR.sup.2 --(CH.sub.2).sub.n --NR.sup.2 R.sup.3, where n=1-10 and R.sup.2 and R.sup.3 are as defined above; NHCO--B--(CH.sub.2).sub.n --NR.sup.2 R.sup.3, where B=oxygen or NH, or ##STR2## where m+y=3-6, and salts thereof. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,180,435 | Remote plasma enhanced CVD method and apparatus for growing an epitaxial semiconductor layer | January 19, 1993 |
| A remote plasma enhanced CVD apparatus and method for growing semiconductor layers on a substrate, wherein a intermediate feed gas, which does not itself contain constituent elements to be deposited, is first activated in an activation region to produce plural reactive species of the feed gas. These reactive species are then spatially filtered to remove selected of the reactive species, leaving only other, typically metastable, species which are then mixed with a carrier gas including constituent elements to be deposited on the substrate. During this mixing, the selected spatially filtered reactive species of the feed gas chemically interacts, i.e., partially dissociates and activates, in the gas phase, the carrier gas, with the process variables being selected so that there is no back-diffusion of gases or reactive species into the feed gas activation region. The dissociated and activated carrier gas along with the surviving reactive species of the feed gas then flows to the substrate. At the substrate, the surviving reactive species of the feed gas further dissociate the carrier gas and order the activated carrier gas species on the substrate whereby the desired epitaxial semiconductor layer is grown on the substrate. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,168,330 | Semiconductor device having a semiconductor substrate interfaced to a dissimilar material by means of a single crystal pseudomorphic interlayer | December 1, 1992 |
| A semiconductor device including a single crystal semiconductor host material having a surface; an ultrathin pseudomorphic single crystal epitaxial interlayer formed on the surface of the host material, wherein the interlayer is formed of a material and has a thickness selected so that the material of the interlayer is elastically deformed on the surface of the host material to match the lattice constant of the interlayer material with the lattice constant of the host material; and a further material incompatible with the host material when interfaced directly with the host material, but compatible with the interlayer, provided on the interlayer and thereby interfaced with the host material to perform a predetermined function with respect to the interlayer and the host material. In a preferred embodiment, the host material is a material selected from the group consisting of Ge, GaAs, InSb, InP, group II-V compounds and alloys thereof; the interlayer material is formed of pseudomorphic silicon, having a thickness of approximately 10 .ANG. and the further material is formed of SiO.sub.2 or a conductive material. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,141,959 | Isoprenoid phospholipase A2 inhibitors and preparations comprising same | August 25, 1992 |
| Compounds of the formula ##STR1## wherein R.sub.1 is CH.dbd.CY--C(CH.sub.3).dbd.CHX wherein X and Y are different and each is of the formula ##STR2## wherein R' and R" independently are H or alkyl of C.sub.1-6 and R.sub.1 includes all possible geometric isomers are demonstrated effective in treating inflammation, both topically and internally. The mechanism appears to be the inhibition of phospholipase A.sub.2 enzymes. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,128,118 | Cocaine receptor binding ligands | July 7, 1992 |
| 3.beta.-[4-iodophenyl]-tropan-2.beta.-carboxylic acid methyl ester tartrate is a high affinity binding ligand for neurotransmitters in mammalian brains. It and its congeners may be employed for imaging and other brain scanning techniques that allow the determination of the presence of cocaine receptors, such as neurotransmitters and the like. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,122,606 | 10,11-methylenedioxy camptothecins | June 16, 1992 |
| The invention relates to a method of producing 20(S)-camptothecin, 20(R)-camptothecin and analogs thereof. The method involves the resolution of an mixture of enantiomers of an intermediate lactone. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,122,526 | Camptothecin and analogs thereof and pharmaceutical compositions and method using them | June 16, 1992 |
| A method for synthesizing camptothecin and camptothecin analogs using a novel hydroxyl-containing tricyclic intermediate and the camptothecin analogs produced by the process. The camptothecin analogs are effective inhibitors of topoisomerase I and show anti-leukemic and anit-tumor activity. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,106,742 | Camptothecin analogs as potent inhibitors of topoisomerase I | April 21, 1992 |
| A method for synthesizing camptothecin and camptothecin analogs using a novel hydroxyl-containing tricyclic intermediate and the camptothecin analogs produced by the process. The camptothecin analogs are effective inhibitors of topoisomerase I and show anti-leukemic and anti-tumor activity. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,073,548 | 11 .beta.-substituted progesterone analogs | December 17, 1991 |
| A 11.beta.-aryl-19-norprogesterone steroid of the formula: ##STR1## wherein (i) R.sup.1 is H, C.sub.1-4 alkyl, C.sub.2-4 alkenyl, C.sub.2-4 alkynyl, OH, OC(O)CH.sub.3, or OC(O)R.sup.5 , wherein R.sup.5 is C.sub.2-8 alkyl, C.sub.2-8 alkenyl, C.sub.2-8 alkynyl or aryl, R.sub.2 is H, R.sup.3 is H, C.sub.1-4 alkyl, C.sub.2-4 alkenyl or C.sub.2-4 alkynyl, R.sup.4 is H, CH.sub.3, F or Cl, R.sup.6 is H, (CH.sub.3).sub.2 N, CH.sub.3 O, CH.sub.3 CO, CH.sub.3 S, CH.sub.3 SO, CH.sub.3 SO.sub.2, and X is O or NOCH.sub.3 ; or (ii) R.sup.1 and R.sup.2 taken together are a carbon-carbon bond and R.sup.3, R.sup.4, R.sup.6 and X are as defined above; or (iii) R.sup.1 and R.sup.3 taken together are --CH.sub.2 -- or --N.dbd.N--CH.sub.2 --, R.sup.2 is H and R.sup.4, R.sup.6 and X are as defined above; or (iv) R.sup.2 and R.sup.3 taken together are .dbd.CH.sub.2 and R.sup.1 , R.sup.4, R.sup.6 and X are as defined above. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,072,626 | Measurement of ultrafine particle size distributions | December 17, 1991 |
| A measurement system for microelectronic clean rooms to measure ultrafine particle size distribution in the range of 0.002 to 0.2 micrometers is provided which includes four screen diffusion stages each connected in series with a condensation nucleus detector. The input to each screen diffusion stage is connected to a localized area to be measured, and the output of each condensation nucleus detector is connected to a vacuum system which simultaneously draws particle bearing air through the four channels. The output signals of the condensation nucleus detectors present particle size distributiion. In one embodiment of the present invention, one or more optical particle detectors are connected in parallel with the diffusion stage-condensation nucleus detectors to expand the distribution measurements to larger sizes. Other embodiments inclulde a manifold probe to probe a localized area, an alarm system actuated when particle levels exceed a predetermined level, and a manifold assembly to minimize vacuum lines passing through the walls of the microelectronic clean room. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,064,823 | Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers | November 12, 1991 |
| Pentacyclic triterpenoid compounds such as .alpha. boswelic acid and its acetate, .beta.-boswellic acid and its acetate, which have an inhibitory effect on topoisomerase I and topoisomerase II, are disclosed. Compositions based on the pentacyclic triterpenoid compounds which can be used to treat various cancers in mammals are also disclosed. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,061,068 | Process for detection of sub-micron particulate contamination on a bare (planar) substrate | October 29, 1991 |
| Particular contamination below about 0.3 microns in average diameter on an IC wafer substrate is detected by forming a film of a volatile liquid on the wafer's surface and observing interference patterns formed by particles during the evaporation process. These interference patterns magnify the "effective" particle size many times, making detection through an optical microscope possible. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,053,512 | Total synthesis of 20(S) and 20(R)-camptothecin and compthothecin derivatives | October 1, 1991 |
| The invention relates to a method of producing 20(S)-comptothecin, 20(R)-camptothecin and analogs thereof. The method involves the resolution of an mixture of enantiomers of an intermediate lactone. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,049,668 | 10,11-methylenedioxy-20(RS)-camptothecin analogs | September 17, 1991 |
| A camptothecin analog having the structure shown below: ##STR1## wherein R is NO.sub.2, NH.sub.2, NHCOCHR.sup.1 NR.sup.2 R.sup.3, where R.sup.1 is the side-chain of an .alpha.-amino acid and R.sup.2 and R.sup.3, independently are hydrogen or a lower alkyl group or R.sup.3 is a peptide unit containing 1-3 amino acid units bonded to the nitrogen through a peptide bond, NHCO--C.sub.2-8 -alkylene-X or NHCO--C.sub.2-8 -alkenylene-X, where X is COOH or CONR.sup.2 --(CH.sub.2).sub.n --NR.sup.2 R.sup.3, n=1-10 and R.sup.2 and R.sup.3 are as defined above, NHCO--Z--(CH.sub.2).sub.n --NR.sup.2 R.sup.3, where z=oxygen or NH, or ##STR2## where m+y=3-6 and salts thereof. | ||
| Abstract | Patent Details (US PTO) | ||
| 5,018,479 | Remote plasma enhanced CVD method and apparatus for growing an epitaxial semconductor layer | May 28, 1991 |
| A remote plasma enhanced CVD apparatus and method for growing semiconductor layers on a substrate, wherein an intermediate feed gas, which does not itself contain constituent elements to be deposited, is first activated in an activation region to produce plural reactive species of the feed gas. These reactive species are then spatially filtered to remove selected of the reactive species, leaving only other, typically metastable, species which are then mixed with a carrier gas including constituent elements to be deposited on the substrate. During this mixing, the selected spatially filtered reactive species of the feed gas chemically interacts, i.e., partially dissociates and activates, in the gas phase, the carrier gas, with the process variables being selected so that there is no back-diffusion of gases or reactive species into the feed gas activation region. The dissociated and activated carrier gas along with the surviving reactive species of the feed gas then flows to the substrate. At the substrate, the surviving reactive species of the feed gas further dissociate the carrier gas and order the activated carrier gas species on the substrate whereby the desired epitaxial semiconductor layer is grown on the substrate. | ||
| Abstract | Patent Details (US PTO) | ||
| 4,981,968 | Synthesis of camptothecin and analogs thereof | January 1, 1991 |
| A method for synthesizing camptothecin and camptothecin analogs using a novel hydroxyl-containing tricyclic intermediate and the camptothecin analogs produced by the process. The camptothecin analogs are effective inhibitors of topoisomerase I and show anti-leukemic and anti-tumor activity. | ||
| Abstract | Patent Details (US PTO) | ||
| 4,972,486 | Method and apparatus for automatic cuing | November 20, 1990 |
| For hard of hearing people, speech sounds are recognized electronically and displayed on eyeglasses at syllable speed, consonants are shown as a symbol resembling a hand sign, and vowels by the symbol's location in a quadrant display, or by color. | ||
| Abstract | Patent Details (US PTO) | ||
| 4,954,490 | 11 .beta.-substituted progesterone analogs | September 4, 1990 |
| A 11.beta.-aryl-19-norprogesterone steroid of the formula: ##STR1## wherein (i) R.sup.1 is H, C.sub.1-4 alkyl, C.sub.2-4 alkenyl, C.sub.2-4 alkynyl, OH, OC(O)CH.sub.3, or OC(O)R.sup.5, wherein R.sup.5 is C.sub.2-8 alkyl, C.sub.2-8 alkenyl, C.sub.2-8 alkynyl or aryl, R.sub.2 is H, R.sup.3 is H, C.sub.1-4 alkyl, C.sub.2-4 alkenyl or C.sub.2-4 alkynyl, R.sup.4 is H, CH.sub.3, F or Cl, R.sup.6 is H, (CH.sub.3).sub.2 N, CH.sub.3 O, CH.sub.3 CO, CH.sub.3 S, CH.sub.3 SO, CH.sub.3 SO.sub.2, and X is O or NOCH.sub.3 ; or (ii) R.sup.1 and R.sup.2 taken together are a carbon-carbon bond and R.sup.3, R.sup.4, R.sup.6 and X are as defined above; or (iii) R.sup.1 and R.sup.3 taken together are --CH.sub.2 -- or --N.dbd.N--CH.sub.2 --, R.sup.2 is H and R.sup.4, R.sup.6 and X are as defined above; or (iv) R.sup.2 and R.sup.3 taken together are .dbd.CH.sub.2 and R.sup.1, R.sup.4, R.sup.6 and X are as defined above. | ||
| Abstract | Patent Details (US PTO) | ||
| 4,923,491 | Centrifugal filter for separating aerosol particles from a gas stream | May 8, 1990 |
| A centrifugal filter for separating aerosol particles from a gas stream including a rotatable hollow hub and at least one pair of disks fixedly mounted in spaced apart relationship on the hub within a stationary housing mounted on the hub. The hub is perforated in the region between the two disks and is coupled to a vacuum pump so that the interior of the hub is at a lower pressure relative to the space between the disks. The hub is rotated, causing rotation of the disks. Aerosol particles in a flow gas are introduced between the disks and the housing at the periphery of the rotating disks. The pressure differential produced at the hub perforations draws the aerosol laden gas toward the hub. As the aerosol laden gas enters between the rotating disks and the housing, it experiences an acceleration to nearly the angular velocity of the disks, which results in a centrifugal force being applied to the aerosol particles in a direction opposite to the drag force exerted by the vacuum pump. The particles in the gas stream remain entrained in the outer periphery where they are removed, while the gas continues its motion toward the hub, thereby effecting separation. | ||
| Abstract | Patent Details (US PTO) | ||
| 4,920,083 | Novel process for the production of ceramic flakes | April 24, 1990 |
| A method for the production of ceramic oxide lakes, comprising the steps of: (i) preparing a colloidal foam by blowing a gas into an aqueous solution comprising a precursor salt of said ceramic oxide flake and a surfactant; (ii) precipitating flakes of said precursor salt in said colloidal foam; and (iii) dry and calcining said precipitated flakes to produce said ceramic oxide flakes. | ||
| Abstract | Patent Details (US PTO) | ||
| 4,905,705 | Impedance cardiometer | March 6, 1990 |
| A heart monitoring system for assessing a patient's cardiac condition. Bioimpedance components induce an electric current through the thorax of a patient's body and a first signal representing amplitude of transthoracic impedance as a function of time is obtained. Electrocardiograph components obtain an electrocardiograph signal from the patient simultaneously with the first signal. First processing circuitry is connected to the bioimpedance components for processing the first signal and producing therefrom a second signal representing cardiovascular hemodynamic changes as a function of time. Second processing circuitry is connected to the electrocardiograph components for measuring changes in the electrocardiograph signal. An analyzer is connected to the first and second processing circuits for producing an output indicating changes in a portion of the second signal over a period of time relative to changes in the electrocardiograph signal over the same period of time. A presentation device presents a visualization of the output of the analyzer for use in providing an assessment of cardiac condition. | ||
| Abstract | Patent Details (US PTO) | ||
| 4,894,456 | Synthesis of camptothecin and analogs thereof | January 16, 1990 |
| A method for synthesizing camptothecin and camptothecin analogs using a novel hydroxyl-containing tricyclic intermediate and the camptothecin analogs produced by the process. The camptothecin analogs are effective inhibitors of topoisomerase I and show anti-leukemic and anti-tumor activity. | ||
| Abstract | Patent Details (US PTO) | ||
| 4,870,030 | Remote plasma enhanced CVD method for growing an epitaxial semiconductor layer | September 26, 1989 |
| A remote plasma enhanced CVD apparatus and method for growing semiconductor layers on a substrate, wherein an intermediate feed gas, which does not itself contain constituent elements to be deposited, is first activated in an activation region to produce plural reactive species of the feed gas. These reactive species are then spatially filtered to remove selected of the reactive species, leaving only other, typically metastable, species which are then mixed with a carrier gas including constituent elements to be deposited on the substrate. During this mixing, the selected spatially filtered reactive species of the feed gas chemically interacts, i.e., partially dissociates and activates, in the gas phase, the carrier gas, with the process variables being selected so that there is no back-diffusion of gases or reactive species into the feed gas activation region. The dissociated and activated carrier gas along with the surviving reactive species of the feed gas then flows to the substrate. At the substrate, the surviving reactive species of the feed gas further dissociate the carrier gas and order the activated carrier gas species on the substrate whereby the desired epitaxial semiconductor layer is grown on the substrate. | ||
| Abstract | Patent Details (US PTO) | ||
| 4,861,763 | 17 .alpha.-(substituted-methyl)-17.beta.-hydroxy/esterified hydroxy steroids and their progestational use | August 29, 1989 |
| Steroids of the formula: ##STR1## which are characterized by a 17.alpha.-cyanomethyl, azidomethyl, methoxymethyl, phenylmethyl, or ethynylmethyl substituent and a 17.beta.-hydroxy/esterified hydroxy substitutent. The steroids of this invention have glucocorticoid, anti-glucocorticoid, progrestational, or anti-progestational activity, depending on the particular structure. | ||
| Abstract | Patent Details (US PTO) | ||
| 4,837,447 | Rasterization system for converting polygonal pattern data into a bit-map | June 6, 1989 |
| A real-time rasterization system for converting plural polygonal pattern data into respective bits of a two-dimensional bit-map, wherein the respective bits of the bit-map and the locations thereof within the bit-map correspond to the shapes and locations of the polygons in a two-dimensional field and wherein the bit-map is divided into plural data stripes, each including plural scan lines having plural bits. The rasterization system converts the plural pattern data of a data stripe into plural linked data entries such that data entries which correspond to polygons intersecting the same scan line are sequentially linked, and includes a double buffer pattern data memory for storing the plural linked data entries; a processor for determining for each scan line the bits thereof intersected by each polygon represented by the respective linked data entries and for producing bit-map data corresponding to the determined bits; a double-buffer bit-map memory coupled to the processor for storing the bit-map data for each scan line of the data stripe; and a double-buffer output register for reading out sequentially the bit-map data stored in the bit-map memory. | ||
| Abstract | Patent Details (US PTO) | ||
| 4,774,236 | 17.alpha.-(substituted-methyl)-17.beta.-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them | September 27, 1988 |
| Steroids of the formula: ##STR1## which are characterized by a 17.alpha.-cyanomethyl, azidomethyl, methoxymethyl, phenylmethyl, or ethynylmethyl substituent and a 17.beta.-hydroxy/esterified hydroxy substituent. The steroids of this invention have glucocorticoid, anti-glucocorticoid, progestational, or anti-progestational activity, depending on the particular structure. | ||
| Abstract | Patent Details (US PTO) | ||
| 4,757,541 | Audio visual speech recognition | July 12, 1988 |
| A method and apparatus for indicating at least some of a sequence of spoken phonemes in which detected sounds are analyzed to determine a group of phonemes to which a phoneme belongs, the lipshape is optically detected and the respective signals correlated by a computer to indicate the detected phoneme. | ||
| Abstract | Patent Details (US PTO) | ||
| 4,714,619 | Aminomalonyl alanine compounds as dietary sweeteners | December 22, 1987 |
| Compounds having relatively long shelf lives in acidic aqueous media and which are useful as sweeteners have the formula ##STR1## or are pharmaceutically acceptable salts thereof, wherein X is --OR or --NHR, or --NH.sub.2, with R being alkyl having 3-10 carbon atoms. | ||
| Abstract | Patent Details (US PTO) | ||
| 4,713,391 | Azabicyloalkane phenyl substituted alkane carboxylates, their preparation and use as anticholinergic agents | December 15, 1987 |
| This invention relates to novel compositions, their preparation and the use thereof as anticholinergic agents in the treatment or prophylaxis of organophosphate or nerve gas poisoning in animals. These compositions and pharmaceutical preparations containing them in their free base form and acid addition salts thereof are represented by the formula ##STR1## wherein R represents lower alkyl groups containing 1 to 7 carbon atoms; R.sup.1 represents hydrogen, phenyl, cyclohexyl, and cyclopentyl; and R.sup.2 represents lower alkyl groups containing 1 to 7 carbon atoms, hydroxymethyl, and hydroxyl. | ||
| Abstract | Patent Details (US PTO) | ||
| 4,704,000 | Vision enhancing system | November 3, 1987 |
| A sight-facilitating apparatus is provided capable of providing magnifications of about 4X to 8X in an aesthetically pleasing manner. An elongated casing has a light entry at one portion thereof and a light exit at an opposite portion thereof. A prismatic telescopic lens system including an objective, an ocular, and the like is mounted within the casing so that light entering the casing throught the light entry passes through the lens system and exits the light exit, with provision for adjusting the focus of the lens system. The objective is mounted within the casing so that the majority of the focal length thereof extends parallel to the direction of elongation of the casing, the light from the first optical element of the lens system being directed along the direction of elongation of the casing. The casing is preferably mounted on top of or incorporated into an eyeglass frame, between the ear pieces, so that the direction of elongation of the casing extends substantially horizontally between the wearer's eyes, with the light exit adjacent a wearer's eye. The wearer may look through the eyeglass lenses and then by tilting his/her eyes with respect to his/her head an angle of about 10.degree., look through the light exit. | ||
| Abstract | Patent Details (US PTO) | ||